EP0871745A1 - Aspergillus arabinofuranosidase - Google Patents

Aspergillus arabinofuranosidase

Info

Publication number
EP0871745A1
EP0871745A1 EP96907403A EP96907403A EP0871745A1 EP 0871745 A1 EP0871745 A1 EP 0871745A1 EP 96907403 A EP96907403 A EP 96907403A EP 96907403 A EP96907403 A EP 96907403A EP 0871745 A1 EP0871745 A1 EP 0871745A1
Authority
EP
European Patent Office
Prior art keywords
enzyme
promoter
sequence
seq
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96907403A
Other languages
German (de)
French (fr)
Inventor
Susan Mampusta Madrid
Preben Rasmussen
Anita Baruch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DuPont Nutrition Biosciences ApS
Danisco US Inc
Original Assignee
Danisco AS
Danisco US Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Danisco AS, Danisco US Inc filed Critical Danisco AS
Publication of EP0871745A1 publication Critical patent/EP0871745A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01055Alpha-N-arabinofuranosidase (3.2.1.55)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241Phenotypically and genetically modified plants via recombinant DNA technology
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Definitions

  • the present invention relates to an enzyme.
  • the present invention relates to a nucleotide sequence coding for the enzyme.
  • the present invention relates to a promoter, wherein the promoter can be used to control the expression of the nucleotide sequence coding for the enzyme.
  • the enzyme of the present invention is an arabinofuranosidase enzyme having arabinoxylan degrading activity.
  • a gene of interest (“GOI")
  • GOI gene of interest
  • tissue of an organism such as a filamentous fungus (such as Aspergillus Niger) or'even a plant crop.
  • the resultant protein or enzyme may be useful for the organism itself.
  • the crop may be made more useful as a feed.
  • the resultant protein or enzyme can be a component of the food composition or it can be used to prepare food compositions, including altering the characteristics or appearance of food compositions. It may even be desirable to use the organism, such as a filamentous fungus or a crop plant, to express non-plant genes, such as for the same purposes.
  • an organism such as a filamentous fungus or a crop plant
  • mammalian genes include interferons, insulin, blood factors and plasminogen activators.
  • micro ⁇ organisms such as filamentous fungi
  • Fruit and vegetable cell walls largely consist of polysaccharide, the major components being pectin, cellulose and xyloglucan (R.R. Selvendran and J.A. Robertson, IFR Report 1989). Numerous cell wall models have been proposed which attempt to incorporate the essential properties of strength and flexibility (P. Albersheim, Sci. Am.
  • the composition of the plant cell wall is complex and variable.
  • Polysaccharides are mainly found in the form of long chains of cellulose (the main structural component of the plant cell wall), hemicellulose (comprising various ⁇ -xylan chains) and pectic substances (consisting of galacturonans and rhamnogalacturonans; arabinans; and galactans and arabinogalactans).
  • pectic substances consisting of galacturonans and rhamnogalacturonans; arabinans; and galactans and arabinogalactans.
  • arabinan One form of plant polysaccharide is arabinan.
  • a review of arabinans may be found in EP-A-0506190.
  • arabinans consist of a main chain of ⁇ - (1 ⁇ 5) groups linked to one another. Side chains are linked -(l ⁇ 3) or sometimes a- (l-*2) to the main -(l-*5)-L-arabinan backbone.
  • l-*2 the main -(l-*5)-L-arabinan backbone.
  • the molecular weight of arabinan is normally about 15 kDa.
  • Arabinans are degraded by enzymes collectively called arabinases.
  • arabinan-degrading activity is the ability of an enzyme to release arabinose residues, either monomers or oligomers, from arabinan backbones or from arabinan-containing side chains of other hemicellulose backbone structures such as arabinogalactans, or even the release of arabinose monomers via the cleavage of the l-*6 linkage between the terminal arabinofuranosyl unit and the intermediate glucosyl unit of monoterpenyl ⁇ -L- arabinofuranosyl glucosides.
  • the activity of the arabinan degrading enzymes of EP-A-0506190 include: a) the ability to cleave (l ⁇ 2)-o_-L-arabinosidic linkages; b) the ability to cleave (l ⁇ 3)-o.-L-arabinosidic linkages; c) the ability to cleave (l-»5)- ⁇ -L-arabinosidic linkages; d) the ability to cleave the 1 ⁇ 6 linkage between the terminal arabinofuranosyl unit and the intermediate glucosyl unit of monoterpenyl ⁇ -L-arabinofuranosyl glucosides.
  • Arabinan-degrading enzymes are known to be produced by a variety of plants and microorganisms, among these, fungi such as those of the genera Aspergillus, Corticiwn, Rhodotorula (Kaji, A. (1984) Adv. Carbohydr. Chem. Biochem. , 42, 383), Dichotomitus (Brillouet et al. (1985) Carbohydrate Research, 144, 113), Ascomycetes and Basidomycetes (Sydow, G. (1977) DDR Patent Application No. 124,812).
  • fungi such as those of the genera Aspergillus, Corticiwn, Rhodotorula (Kaji, A. (1984) Adv. Carbohydr. Chem. Biochem. , 42, 383), Dichotomitus (Brillouet et al. (1985) Carbohydrate Research, 144, 113), Ascomycetes and Basidom
  • xylan Another plant polysaccharide is xylan, whose major monosaccharide unit is xylose.
  • Xylans are abundant components of the hemicelluloses.
  • the dominant hemicellulose is an arabinoxylan, in which arabinose side chains are attached to a backbone of xylose residues.
  • Arabinoxylans are carbohydrates found in the cell wall of cereals. A review of arabinoxylans and the enzymatic degradation thereof may be found in Voragen et al (1992 Characterisation of Cereal Arabinoxylans, Xylans and Xylanases pages 51-67, edited by J. Visser published by Elsevier Science Publishers).
  • arabinoxylans comprise a xylose backbone linked together via 0-1 ,4- bonds.
  • the xylose backbone is substituted with L-arabinose residues which are linked via -1 bonds to the 2 or 3 position of the xylose residues.
  • the xylose residues can be single or double substituted.
  • the xylose residues can be substituted with acetyl groups, glucuronic acid and various other carbohydrates.
  • the arabinose residues can be further substituted with phenolic acids such as ferulic acid and coumaric acid. The degree and kind of substitution depends on the source of the particular arabinoxylan.
  • Arabinoxylans are found in cereal cell wall where they are part of the secondary cell wall. Arabinoxylans form about 3 % of wheat flour - part of it is water soluble (WSP), pan of it is water insoluble (WIP) .
  • the arabinoxylans amount to only about 3 % of wheat the importance of the arabinoxylan fraction is much higher.
  • the arabinoxylans of cereals act as hydrocoUoids, as they form a gel like structure with water.
  • the arabinoxylans of wheat flour bind up to 30% of the water in a dough despite the fact that they amount to only 3 % of the dry matter.
  • arabinoxylans bind water they increase the viscosity of the ground cereals and to such an extent that the cereals can become difficult to manage.
  • the rheological properties of several systems where ground cereals are used can be manipulated using enzymes that degrade arabinoxylans.
  • enzymes that degrade arabinoxylans In modern bakery it is advantageous to reduce the viscosity of the dough in order to reduce the energy needed to process the doughs and also to get a higher volume of the bread. This is usually achieved by using enzymes that can degrade the xylose backbone of arabinoxylans.
  • Enzymes that only cleave the arabinose side chains from the xylan backbone of arabinoxylan are, for the purposes of this application, collectively called arabinoxylan degrading enzymes.
  • arabinoxylans in the cereals can increase the viscosity of the fluids in the intestines of the animals after the feeds have been ingested. This is a problem as it causes discomfort, such as indigestion, to the animals. Also, the nutritive value of the feeds is reduced.
  • enzymes that degrade the arabinoxylan such as xylanases
  • some enzymes that degrade the arabinoxylans require the presence of unsubstituted backbones and so their activity can be limited. Further discussions on arabinoxylans can be found in Xylans and Xylanases (1992, edited by J. Visser published by Elsevier Science Publishers).
  • An arbinoxylan degrading enzyme is (l ,4)- ⁇ -D-arabinoxylan arabinofuranohydrolase (AXH), as described by Kormelink et al 1991 (Kormelink, F.J.M. , Searle-Van Leeuwen M.J.F. , Wood. T.M. , Voragen, A.G.J.(1991) Purification and characterization of a (1 ,4)-/3-D-arabinoxylan arabinofuranohydrolase from Aspergillus awamori. Appl. Micro- biol. Biotechnol. 25:753-758). However, this document provides no sequence data for the enzyme or the nucleotide sequence coding for same or for the promoter for the same.
  • the present invention seeks to provide an enzyme having arabinoxylan degrading activity; preferably wherein the enzyme can be prepared in certain or specific cells or tissues, such as in just a specific cell or tissue, of an organism, typically a filamentous fungus, preferably of the genus Aspergillus, such as Aspergillus niger, or even a plant.
  • the present invention seeks to provide a GOI coding for the enzyme that can be expressed preferably in specific cells or tissues, such as in certain or specific cells or tissues, of an organism, typically a filamentous fungus, preferably of the genus Aspergillus, such as Aspergillus niger, or even a plant.
  • the present invention seeks to provide a promoter that is capable of directing expression of a GOI, such as a nucleotide sequence coding for the enzyme according to the present invention, preferably in certain specific cells or tissues, such as in just a specific cell or tissue, of an organism, typically a filamentous fungus, preferably of the genus Aspergillus, such as Aspergillus niger, or even a plant.
  • a promoter is used in Aspergillus wherein the product encoded by the GOI is excreted from the host organism into the surrounding medium.
  • the present invention seeks to provide constructs, vectors, plasmids, cells, tissues, organs and organisms comprising the GOI and/or the promoter, and methods of expressing the same, preferably in specific cells or tissues, such as expression in just a specific cell or tissue, of an organism, typically a filamentous fungus, preferably of the genus Aspergillus, or even a plant.
  • an enzyme obtainable from Aspergillus, wherein the enzyme has the following characteristics: a MW of 33,270 D ⁇ 50 D; a pi value of about 3.7; arabinoxylan degrading activity; a pH optima of from about 2.5 to about 7.0 (more especially from about 3.3 to about 4.6, more especially about 4); a temperature optima of from about 40°C to about 60°C (more especially from about 45°C to about 55°C, more especially about 50°C); and wherein the enzyme is capable of cleaving arabinose from the xylose backbone of an arabinoxylan.
  • an enzyme having the sequence shown as SEQ. I.D. No. 1 or a variant, homologue or fragment thereof.
  • nucleotide sequence coding for the enzyme according to the present invention there is provided a nucleotide sequence coding for the enzyme according to the present invention.
  • nucleotide sequence having die sequence shown as SEQ. I.D. No. 2 or a variant, homologue or fragment thereof or a sequence complementary thereto.
  • a promoter having the sequence shown as SEQ. I.D. No. 3 or a variant, homologue or fragment thereof or a sequence complementary thereto.
  • a terminator having the nucleotide sequence shown as SEQ. I.D. No. 13 or a variant, homologue or fragment thereof or a sequence complementary thereto.
  • a signal sequence having the nucleotide sequence shown as SEQ. I.D. No. 14 or a variant, homologue or fragment thereof or a sequence complementary thereto.
  • a ninth aspect of the present invention there is provided a process for expressing a GOI by use of a promoter, wherein the promoter is the promoter according to the present invention.
  • a combination of enzymes to degrade an arabinoxylan comprising an enzyme according to the present invention and a xylanase.
  • plasmid NCIMB 40703 or a nucleotide sequence obtainable therefrom for expressing an enzyme capable of degrading arabinoxylan or for controlling the expression thereof or for controlling the expression of another GOI.
  • a signal sequence having the sequence shown as SEQ. I.D. No. 15 or a variant, homologue or fragment thereof.
  • an arabinofuranosidase enzyme having arabinoxylan degrading activity, which is immunologicaily reactive with an antibody raised against a purified arabinofuranosidase enzyme having the sequence shown as SEQ. I.D. No. 1.
  • an arabinofuranosidase promoter wherein the promoter is inducible by an intermediate in xylose metabolism.
  • a seventeenth aspect of the present invention there is provided a process of reducing the viscosity of a branched substrate wherein the enzyme degrades the branches of the substrate but not the backbone of the substrate.
  • aspects of the present invention include constructs, vectors, plasmids, cells, tissues, organs and transgenic organisms comprising the aforementioned aspects of the present invention.
  • aspects of the present invention include methods of expressing or allowing expression or transforming any one of the nucleotide sequence, the construct, the plasmid, the vector, the cell, the tissue, the organ or the organism, as well as the products thereof.
  • Additional aspects of the present invention include uses of the promoter for expressing GOIs in culture media such as a broth or in a transgenic organism. Further aspects of the present invention include uses of the enzyme for preparing or treating foodstuffs, including animal feed.
  • the enzyme is coded by the nucleotide sequence shown as SEQ. I.D. No. 2 or a variant, homologue or fragment thereof or a sequence complementary thereto.
  • nucleotide sequence has the sequence shown as SEQ. I.D. No. 2 or a variant, homologue or fragment thereof or a sequence complementary thereto.
  • nucleotide sequence is operatively linked to a promoter.
  • the promoter comprises the sequence CCAAT.
  • the promoter is the promoter having the sequence shown as SEQ. I.D. No. 3 or a variant, homologue or fragment thereof or a sequence complementary thereto.
  • the promoter comprises the 100 bps sequence from the Xma 111 to the BamHl sites.
  • the promoter of the present invention is operatively linked to a GOI.
  • the GOI comprises a nucleotide sequence according to the present invention.
  • the transgenic organism is a fungus.
  • the transgenic organism is a filamentous fungus, more preferably of the genus Aspergillus.
  • the transgenic organism is a plant.
  • the enzyme is used in combination with a xylanase, preferably an endoxylanase.
  • a xylanase preferably an endoxylanase.
  • Highly preferred embodiments of each of the aspects of the present invention do not include any one of the native enzyme, the native promoter or the native nucleotide sequence in its natural environment.
  • the vector such as an expression vector or a transformation vector
  • the cell, the tissue, the organ, the organism or the transgenic organism is present in combination with at least one GOI.
  • the promoter and the GOI are stably incorporated within the transgenic organism's genome.
  • the transgenic organism is a filamentous fungus, preferably of the genus Aspergillus, more preferably Aspergillus niger.
  • the transgenic organism can even be a plant, such as a monocot or dicot plant.
  • a highly preferred embodiment is an enzyme obtainable from Aspergillus, wherein the enzyme has the following characteristics: a MW of 33,270 D ⁇ 50 D; a pi value of about 3.7; arabinoxylan degrading activity; a pH optima of from about 2.5 to about 7.0 (more especially from about 3.3 to about 4.6, more especially about 4); a temperature optima of from about 40°C to about 60°C (more especially from about 45°C to about 55°C, more especially about 50°C); and wherein the enzyme is capable of cleaving arabinose from the xylose backbone of an arabinoxylan; wherein the enzyme has the sequence shown as SEQ. I.D. No. 1 or a variant, homologue or fragment thereof.
  • Another highly preferred embodiment is an enzyme obtainable from Aspergillus, wherein the enzyme has the following characteristics: a MW of 33,270 D ⁇ 50 D; a pi value of about 3.7; arabinoxylan degrading activity; a pH optima of from about 2.5 to about 7.0 (more especially from about 3.3 to about 4.6, more especially about 4); a temperature optima of from about 40°C to about 60°C (more especially from about 45°C to about 55°C, more especially about 50°C); and wherein the enzyme is capable of cleaving arabinose from the xylose backbone of an arabinoxylan; wherein the enzyme is coded by the nucleotide sequence shown as SEQ. I.D. No. 2 or a variant, homologue or fragment thereof or a sequence complementary thereto.
  • the advantages of the present invention are that it provides a means for preparing an arabinofuranosidase enzyme having arabinoxylan degrading activity and the nucleotide sequence coding for the same. In addition, it provides a promoter that can control the expression of that, or another, nucleotide sequence.
  • the enzyme of the present invention can affect the viscosity of ground cereals, such as dough, to ease the handling thereof and for example to get a higher volume of the bread.
  • the enzyme of the present invention is also advantageous for feed because it degrades arabinoxylan and thus increases the nutritive value of the feed. In addition, it reduces the viscosity of the arabinoxylan in the intestine of the animals and so reduces or prevents indigestion.
  • the combination of the use of the enzyme of the present invention with a xylanase is particularly advantageous because the enzyme of the present invention and the xylanase have a surprising and unexpected synergistic effect with each other.
  • the enzyme of the present invention increases the degradative effect of the xylanase, and the xylanase increases the degradative effect of the enzyme of the present invention. It is believed that the activity of the xylanase is increased because the enzyme of the present invention provides a polysaccharide substrate having fewer substituted groups.
  • the present invention therefore provides an enzyme having arabinoxylan degrading activity wherein the enzyme can be prepared in certain or specific cells or tissues, such as in just a specific cell or tissue, of an organism, typically a filamentous fungus, preferably of the genus Aspergillus, such as Aspergillus niger.
  • the enzyme may even be prepared in a plant. More in particular, the enzyme of the present invention is capable of specifically cleaving arabinose from the xylose backbone of arabinoxylan.
  • arabinofuranosidase of the present invention is different from the arabinofuranosidases previously known.
  • the previous described arabinofuranosidases - such as those of EP-A-0506190 - are characterised by their ability to degrade unbranched arabinan, and are assayed using p-nitrophenyl-arabinoside.
  • the arabinofuranosidase of the present invention does not degrade unbranched arabinan, and only a minor activity is seen on nitrophenyl-arabinoside.
  • the arabinofuranosidase of the present invention is useful for degrading arabinoxylan. Therefore, the arabinofuranosidase of the present invention is quite different from the previous isolated arabinofuranosidases.
  • the present invention provides a GOI coding for the enzyme that can be expressed preferably in specific cells or tissues, such as in certain or specific cells or tissues, of an organism, typically a filamentous fungus, preferably of the genus Aspergillus, such as Aspergillus niger.
  • the GOI may even be expressed in a plant.
  • the present invention provides a promoter that is capable of directing expression of a GOI, such as a nucleotide sequence coding for the enzyme according to the present invention, preferably in certain specific cells or tissues, such as in just a specific cell or tissue, of an organism, typically a filamentous fungus, preferably of the genus Aspergillus, such as Aspergillus niger, or even a plant.
  • a GOI such as a nucleotide sequence coding for the enzyme according to the present invention
  • the promoter is used in Aspergillus wherein the product encoded by the GOI is excreted from the host organism into the surrounding medium.
  • the promoter may even be tailored (if necessary) to express a GOI in a plant.
  • the present invention also provides constructs, vectors, plasmids, cells, tissues, organs and organisms comprising the GOI and/or the promoter, and methods of expressing the same, preferably in specific cells or tissues, such as expression in just a specific cell or tissue, of an organism, typically a filamentous fungus, preferably of the genus Aspergillus, or even a plant.
  • variant in relation to the enzyme include any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) amino acid from or to the sequence providing the resultant amino acid sequence has arabinoxylan degrading activity, preferably having at least the same activity of the enzyme shown in the sequence listings (SEQ I.D. No. 1 or 12).
  • homologue covers homology with respect to structure and/or function providing the resultant enzyme has arabinoxylan degrading activity.
  • sequence homology preferably there is at least 75%, more preferably at least 85% , more preferably at least 90% homology to SEQ ID NO. 1 shown in the attached sequence listings. More preferably there is at least 95%, more preferably at least 98%, homology to SEQ ID NO. 1 shown in the attached sequence listings.
  • variant in relation to the nucleotide sequence coding for the enzyme include any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) nucleic acid from or to the sequence providing the resultant nucleotide sequence codes for an enzyme having arabinoxylan degrading activity, preferably having at least the same activity of the enzyme shown in the sequence listings (SEQ I.D. No. 2 or 12).
  • homologue covers homology with respect to structure and/or function providing the resultant nucleotide sequence codes for an enzyme having arabinoxylan degrading activity.
  • sequence homology preferably there is at least 75 %, more preferably at least 85%, more preferably at least 90% homology to SEQ ID NO. 2 shown in the attached sequence listings. More preferably there is at least 95%, more preferably at least 98%, homology to SEQ ID NO. 2 shown in the attached sequence listings.
  • variant in relation to the promoter include any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) nucleic acid from or to the sequence providing the resultant nucleotide sequence has the ability to act as a promoter in an expression system - such as the transformed cell or the transgenic organism according to the present invention.
  • the term “homologue” covers homology with respect to structure and/or function providing the resultant nucleotide sequence has the ability to act as a promoter.
  • sequence homology preferably there is at least 75 % , more preferably at least 85 % , more preferably at least 90% homology to SEQ ID NO. 3 shown in the attached sequence listings. More preferably there is at least 95% , more preferably at least 98%, homology to SEQ ID NO. 3 shown in the attached sequence listings.
  • variants in relation to the terminator or signal nucleotide sequences include any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) nucleic acid from or to the sequence providing the resultant nucleotide sequence has the ability to act as a terminator or codes for an amino acid sequence that has the ability to act as a signal sequence respectively in an expression system - such as the transformed cell or the transgenic organism according to the present invention.
  • the term “homologue” covers homology with respect to structure and/or function providing the resultant nucleotide sequence has the ability to act as or code for a terminator or signal respectively.
  • sequence homology preferably there is at least 75%, more preferably at least 85 %, more preferably at least 90% homology to SEQ ID NO.s 13 and 14 (respectively) shown in the attached sequence listings. More preferably there is at least 95 % , more preferably at least 98%, homology to SEQ ID NO.s 13 and 14 (respectively) shown in the attached sequence listings.
  • variant in relation to the signal amino acid sequence include any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) amino acid from or to the sequence providing the resultant sequence has the ability to act as a signal sequence in an expression system - such as the transformed cell or the transgenic organism according to the present invention.
  • homologue covers homology with respect to structure and/or function providing the resultant nucleotide sequence has the ability to act as or code for a signal respectively.
  • sequence homology preferably there is at least 75%, more preferably at least 85%, more preferably at least 90% homology to SEQ ID NO 15 shown in the attached sequence listings. More preferably there is at least 95 %, more preferably at least 98%, homology to SEQ ID NO 15 shown in the attached sequence listings.
  • nucleotide sequences that can hybridise to the nucleotide sequences of the coding sequence or the promoter sequence, respectively.
  • nucleotide in relation to the present invention includes genomic DNA, cDNA, synthetic DNA, and RNA. Preferably it means DNA, more preferably cDNA for the coding sequence of the present invention.
  • construct which is synonymous with terms such as “conjugate” , “cassette” and “hybrid” - includes a GOI directly or indirectly attached to a promoter.
  • An example of an indirect attachment is the provision of a suitable spacer group such as an intron sequence, such as the SAi-intron or the ADH intron, intermediate the promoter and the GOI.
  • fused in relation to the present invention which includes direct or indirect attachment.
  • the terms do not cover the natural combination of the gene coding for the enzyme ordinarily associated with the wild type gene promoter and when they are both in their natural environment.
  • a highly preferred embodiment is the or a GOI being operatively linked to a or the promoter.
  • the construct may even contain or express a marker which allows for the selection of the genetic construct in, for example, a filamentous fungus, preferably of the genus Aspergillus, such as Aspergillus niger, or plants, preferably cereals, such as maize, rice, barley etc. , into which it has been transferred.
  • a marker which allows for the selection of the genetic construct in, for example, a filamentous fungus, preferably of the genus Aspergillus, such as Aspergillus niger, or plants, preferably cereals, such as maize, rice, barley etc. , into which it has been transferred.
  • Various markers exist which may be used such as for example those encoding mannose-6-phosphate isomerase (especially for plants) or those markers that provide for antibiotic resistance - e.g. resistance to G418, hygromycin, bleomycin, kanamycin and gentamycin.
  • the term "vector” includes expression vectors and transformation vectors.
  • expression vector means a construct capable of in vivo or in vitro expression.
  • transformation vector means a construct capable of being transferred from one species to another - such as from an E.coli plasmid to a filamentous fungus, preferably of the genus Aspergillus. It may even be a construct capable of being transferred from an E.coli plasmid to an Agrobacterium to a plant.
  • tissue includes tissue per se and organ.
  • organism in relation to the present invention includes any organism that could comprise the promoter according to the present invention and/or the nucleotide sequence coding for the enzyme according to the present invention and/or products obtained therefrom, wherein the promoter can allow expression of a GOI and/or wherein the nucleotide sequence according to the present invention can be expressed when present in the organism.
  • the organism is a filamentous fungus, preferably of the genus Aspergillus, more preferably Aspergillus niger.
  • transgenic organism in relation to the present invention includes any organism that comprises the promoter according to the present invention and/or the nucleotide sequence coding for the enzyme according to the present invention and/or products obtained therefrom, wherein the promoter can allow expression of a GOI and/or wherein the nucleotide sequence according to the present invention can be expressed within the organism.
  • the promoter and/or the nucleotide sequence is (are) incorporated in the genome of the organism.
  • the transgenic organism is a filamentous fungus, preferably of the genus Aspergillus, more preferably Aspergillus niger. Therefore, the transgenic organism of the present invention includes an organism comprising any one of, or combinations of, the promoter according to the present invention, the nucleotide sequence coding for the enzyme according to the present invention, constructs according to the present invention, vectors according to the present invention, plasmids according to the present invention, cells according to the present invention, tissues according to the present invention or the products thereof.
  • the transgenic organism can comprise a GOI, preferably an exogenous nucleotide sequence, under the control of the promoter according to the present invention.
  • the transgenic organism can also comprise the nucleotide sequence coding for the enzyme of the present invention under the control of a promoter, which may be the promoter according to the present invention.
  • the transgenic organism does not comprise the combination of the promoter according to the present invention and the nucleotide sequence coding for the enzyme according to the present invention, wherein both the promoter and the nucleotide sequence are native to that organism and are in their natural environment.
  • the present invention does not cover the native nucleotide coding sequence according to the present invention in its natural environment when it is under the control of its native promoter which is also in its natural environment.
  • the present invention does not cover the native enzyme according to the present invention when it is in its natural environment and when it has been expressed by its native nucleotide coding sequence which is also in its natural environment and when that nucleotide sequence is under the control of its native promoter which is also in its natural environment.
  • promoter is used in the normal sense of the art, e.g. an RNA polymerase binding site in the Jacob-Mond theory of gene expression.
  • the promoter of the present invention is capable of expressing a GOI, which can be the nucleotide sequence coding for the enzyme of the present invention.
  • the nucleotide sequence according to the present invention is under the control of a promoter that allows expression of the nucleotide sequence.
  • the promoter need not necessarily be the same promoter as that of the present invention.
  • the promoter may be a cell or tissue specific promoter. If, for example, the organism is a plant then the promoter can be one that affects expression of the nucleotide sequence in any one or more of stem, sprout, root and leaf tissues.
  • the promoter for the nucleotide sequence of the present invention can be the ⁇ -Amy 1 promoter (otherwise known as the Amy 1 promoter, the Amy 637 promoter or the ⁇ -Amy 637 promoter) as described in our co-pending UK patent application No. 9421292.5 filed 21 October 1994. That promoter comprises the sequence shown in Figure 1.
  • the promoter for the nucleotide sequence of the present invention can be the ⁇ -Amy 3 promoter (otherwise known as the Amy 3 promoter, the Amy 351 promoter or the ⁇ -Amy 351 promoter) as described in our co-pending UK patent application No. 9421286.7 filed 21 October 1994. That promoter comprises the sequence shown in Figure 2.
  • the promoter is the promoter of the present invention.
  • the promoters could additionally include features to ensure or to increase expression in a suitable host.
  • the features can be conserved regions such as a Pribnow Box or a TATA box.
  • the promoters may even contain other sequences to affect (such as to maintain, enhance, decrease) the levels of expression of the GOI.
  • suitable other sequences include the S ⁇ i-intron or an ADH intron.
  • Other sequences include inducible elements - such as temperature, chemical, light or stress inducible elements.
  • TMV 5' signal sequence see Sleat Gene 217 [1987] 217-225; and Dawson Plant Mol. Biol. 23 [1993] 97).
  • the present invention also encompasses combinations of promoters and/or nucleotide sequences coding for proteins or enzymes and/or elements.
  • the present invention encompasses the combination of a promoter according to the present invention operatively linked to a GOI, which could be a nucleotide sequence according to the present invention, and another promoter such as a tissue specific promoter operatively linked to the same or a different GOI.
  • the present invention also encompasses the use of promoters to express a nucleotide sequence coding for the enzyme according to the present invention, wherein a part of the promoter is inactivated but wherein the promoter can still function as a promoter. Partial inactivation of a promoter in some instances is advantageous.
  • Amy 351 promoter it is possible to inactivate a part of it so that the partially inactivated promoter expresses GOIs in a more specific manner such as in just one specific tissue type or organ.
  • inactivated means partial inactivation in the sense that the expression pattern of the promoter is modified but wherein the partially inactivated promoter still functions as a promoter.
  • the modified promoter is capable of expressing a GOI in at least one (but not all) specific tissue of the original promoter.
  • One such promoter is the Amy 351 promoter described above.
  • partial inactivation examples include altering the folding pattern of the promoter sequence, or binding species to parts of the nucleotide sequence, so that a part of the nucleotide sequence is not recognised by, for example, RNA polymerase.
  • Another, and preferable, way of partially inactivating the promoter is to truncate it to form fragments thereof. Another way would be to mutate at least a part of the sequence so that the RNA polymerase can not bind to that part or another part.
  • Another modification is to mutate the binding sites for regulatory proteins for example the CreA protein known from filamentous fungi to exert carbon catabolite repression, and thus abolish the catabolite repression of the native promoter.
  • a GOI with reference to the present invention means any gene of interest.
  • a GOI can be any nucleotide that is either foreign or natural to the organism (e.g. filamentous fungus, preferably of the genus Aspergillus, or a plant) in question.
  • Typical examples of a GOI include genes encoding for proteins and enzymes that modify metabolic and catabolic processes.
  • the GOI may code for an agent for introducing or increasing pathogen resistance.
  • the GOI may even be an antisense construct for modifying the expression of natural transcripts present in the relevant tissues.
  • the GOI may even code for a non- natural protein of a filamentous fungus, preferably of the genus Aspergillus, or a compound that is of benefit to animals or humans.
  • the GOI could code for a pharmaceutically active protein or enzyme such as any one of the therapeutic compounds insulin, interferon, human serum albumin, human growth factor and blood clotting factors.
  • the transformed cell or organism could prepare acceptable quantities of the desired compound which would be easily retrievable from, the cell or organism.
  • the GOI may even be a protein giving nutritional value to a food or crop. Typical examples include plant proteins that can inhibit the formation of anti-nutritive factors and plant proteins that have a more desirable amino acid composition (e.g. a higher lysine content than a non-transgenic plant).
  • the GOI may even code for an enzyme that can be used in food processing such as chymosin, thaumatin and ⁇ -galactosidase.
  • the GOI can be a gene encoding for any one of a pest toxin, an antisense transcript such as that for patatin or ⁇ -amylase, ADP-glucose pyrophosphorylase (e.g. see EP-A-0455316), a protease antisense or a glucanase.
  • an antisense transcript such as that for patatin or ⁇ -amylase, ADP-glucose pyrophosphorylase (e.g. see EP-A-0455316), a protease antisense or a glucanase.
  • the GOI can be the nucleotide sequence coding for the ⁇ -amylase enzyme which is the subject of our co-pending UK patent application 9413439.2 filed on 4 July 1994, d e sequence of which is shown in Figure 3.
  • the GOI can be the nucleotide sequence coding for the ⁇ -amylase enzyme which is the subject of our co-pending UK patent application 9421290.9 filed on 21 October 1994, the sequence of which is shown in Figure 4.
  • the GOI can be any of the nucleotide sequences coding for the ADP-glucose pyrophosphorylase enzymes which are the subject of our co-pending PCT patent application PCT/EP94/01082 filed 7 April 1994, the sequences of which are shown in Figures 5 and 6.
  • the GOI can be any of the nucleotide sequences coding for the ⁇ - glucan lyase enzyme which are described in our co-pending PCT patent application PCT/EP94/03397 filed 15 October 1994, the sequences of which are shown in Figures 7-10.
  • the GOI is a nucleotide sequence coding for the enzyme according to the present invention.
  • a preferred host organism is of the genus Aspergillus, such as Aspergillus niger.
  • the transgenic Aspergillus according to the present invention can be prepared by following the teachings of Rambosek . and Leach, J. 1987 (Recombinant DNA in filamentous fungi: Progress and Prospects. CRC Crit. Rev. Biotechnol. 6:357- 393), Davis R.W. 1994 (Heterologous gene expression and protein secretion in Asperg ⁇ illus. In: Martinelli S.D., Kinghorn J.R.( Editors) Aspergillus: 50 years on. Progress in industrial microbiology voi 29. Elsevier Amsterdam 1994.
  • Filamentous fungi have during almost a century been widely used in industry for produc ⁇ tion of organic compounds and enzymes. Traditional Japanese koji and soy fermentations have used Aspergillus sp for hundreds of years. In this century Aspergillus niger has been used for production of organic acids particular citric acid and for production of various enzymes for use in industry. There are two major reasons for that filamentous fungi have been so widely used in industry. First filamentous fungi can produce high amounts of extracellular products, for example enzymes and organic compounds such as antibiotics or organic acids. Second filamentous fungi can grow on low cost substrates such as grains, bran, beet pulp etc. The same reasons have made filamentous fungi attractive organisms as hosts for heterologous expression according to the present invention.
  • expression constructs are prepared by inserting a GOI (such as an amylase or SEQ. I.D. No. 2) into a construct designed for expression in filamentous fungi.
  • a GOI such as an amylase or SEQ. I.D. No. 2
  • the constructs contain the promoter according to the present invention (or if desired another promoter if the GOI codes for the enzyme according to the present invention) which is active in fungi.
  • promoters other than that of the present invention include a fungal promoter for a highly expressed extracellular enzyme, such as the glucoamylase promoter or the ⁇ -amylase promoter.
  • the GOI can be fused to a signal sequence (such as that of the present invention or another suitable sequence) which directs the protein encoded by the GOI to be secreted.
  • a signal sequence of fungal origin is used, such as diat of the present invention.
  • a terminator active in fungi ends the expression system, such as that of the present invention.
  • Another type of expression system has been developed in fungi where the GOI is fused to a smaller or a larger part of a fungal gene encoding a stable protein. This can stabilize the protein encoded by the GOI.
  • a cleavage site recognized by a specific protease, can be introduced between the fungal protein and the protein encoded by the GOI, so the produced fusion protein can be cleaved at this position by the specific protease thus liberating the protein encoded by the GOI ("POI").
  • POI protein encoded by the GOI
  • Such a fusion leads to cleavage in vivo resulting in protection of the POI and production of POI and not a larger fusion protein.
  • Heterologous expression in Aspergillus has been reported for several genes coding for bacterial, fungal, vertebrate and plant proteins. The proteins can be deposited intracellularly if the GOI is not fused to a signal sequence. Such proteins will accumulate in the cytoplasm and will usually not be glycosylated which can be an advantage for some bacterial proteins. If the GOI is equipped with a signal sequence the protein will accumulate extracellulary.
  • heterologous proteins are not very stable when they are secreted into the culture fluid of fungi. Most fungi produce several extracellular proteases which degrade heterologous proteins. To avoid this problem special fungal strains with reduced protease production have been used as host for heterologous production.
  • filamentous fungi For the transformation of filamentous fungi, several transformation protocols have been developed for many filamentous fungi (Ballance 1991, ibid). Many of them are based on preparation of protoplasts and introduction of DNA into the protoplasts using PEG and Ca 2+ ions. The transformed protoplasts then regenerate and the transformed fungi are selected using various selective markers. Among the markers used for transformation are a number of auxotrophic markers such as argB, ⁇ rpC, niaD and pyrG, antibiotic resistance markers such as benomyl resistance, hygromycin resistance and phleomycin resistance. A very common used transformation marker is the amdS gene of A. nidulans which in high copy number allows the fungus to grow with acrylamide as the sole nitrogen source.
  • auxotrophic markers such as argB, ⁇ rpC, niaD and pyrG
  • antibiotic resistance markers such as benomyl resistance, hygromycin resistance and phleomycin resistance.
  • the basic principle in the construction of genetically modified plants is to insert genetic information in the plant genome so as to obtain a stable maintenance of the inserted genetic material.
  • the present invention relates to a vector system which carries a promoter or nucleotide sequence or construct according to the present invention and which is capable of introducing the promoter or nucleotide sequence or construct into the genome of an organism, such as a plant.
  • the vector system may comprise one vector, but it can comprise two vectors. In the case of two vectors, the vector system is normally referred to as a binary vector system.
  • Binary vector systems are described in further detail in Gynheung An et al. (1980), Binary Vectors, Plant Molecular Biology Manual A3, 1-19.
  • One extensively employed system for transformation of plant cells with a given promoter or nucleotide sequence or construct is based on the use of a Ti plasmid from Agrobacte ⁇ um tumefaciens or a Ri plasmid from Agrobacte ⁇ um rhizogenes An et al. (1986), Plant Physiol. 81 , 301-305 and Butcher D.N. et al. (1980), Tissue Culture Methods for Plant Pathologists, eds. : D.S. Ingrams and J.P. Helgeson, 203-208.
  • Ti and Ri plasmids have been constructed which are suitable for the construction of the plant or plant cell constructs described above.
  • a non-limiting example of such a Ti plasmid is pGV3850.
  • the promoter or nucleotide sequence or construct of the present invention should preferably be inserted into the Ti-plasmid between the terminal sequences of the T-DNA or adjacent a T-DNA sequence so as to avoid disruption of the sequences immediately surrounding the T-DNA borders, as at least one of these regions appear to be essential for insertion of modified T-DNA into the plant genome.
  • the vector system of the present invention is preferably one which contains the sequences necessary to infect the plant (e.g. the vir region) and at least one border pan of a T-DNA sequence, the border part being located on the same vector as the genetic construct.
  • the vector system is preferably an Agrobacte ⁇ um tumefaciens Ti-plasmid or an Agrobacterium rhizogenes Ri-plasmid or a derivative thereof, as these plasmids are well-known and widely employed in the construction of transgenic plants, many vector systems exist which are based on these plasmids or derivatives thereof.
  • the promoter or nucleotide sequence or construct of die present invention may be first constructed in a microorganism in which the vector can replicate and which is easy to manipulate before insertion into the plant.
  • An example of a useful microorganism is E. coli, but other microorganisms having the above properties may be used.
  • a vector of a vector system as defined above has been constructed in £. coli, it is transferred, if necessary, into a suitable Agrobacterium strain, e.g. Agrobacterium tumefaciens.
  • the Ti-plasmid harbouring the promoter or nucleotide sequence or construct of the invention is thus preferably transferred into a suitable Agrobacte ⁇ um strain, e.g. A. tumefaciens, so as to obtain an Agrobacte ⁇ um cell harbouring the promoter or nucleotide sequence or construct of the invention, which DNA is subsequently transferred into the plant cell to be modified.
  • cloning vectors which contain a replication system in E. coli and a marker which allows a selection of the transformed cells.
  • the vectors contain for example pBR 322, pUC series, Ml 3 mp series, pACYC 184 etc.
  • the nucleotide or construct or promoter of the present invention can be introduced into a suitable restriction position in the vector.
  • the contained plasmid is used for the transformation in E. coli.
  • the E. coli cells are cultivated in a suitable nutrient medium and then harvested and lysed.
  • the plasmid is then recovered.
  • sequence analysis there is generally used sequence analysis, restriction analysis, electrophoresis and further biochemical-molecular biological methods. After each manipulation, the used DNA sequence can be restricted and connected with the next DNA sequence. Each sequence can be cloned in die same or different plasmid.
  • the presence and/or insertion of further DNA sequences may be necessary. If, for example, for the transformation the Ti- or Ri-plasmid of the plant cells is used, at least die right boundary and often however the right and the left boundary of the Ti- and Ri-plasmid T-DNA, as flanking areas of the introduced genes, can be connected.
  • T-DNA for the transformatron of plant cells has been intensively studied and is described in EP-A-120516; Hoekema, in: The Binary Plant Vector System Offset-drukkerij Kanters B.B. , Alblasserdam, 1985, Chapter V; Fraley, et al. , Crit. Rev. Plant Sci. , 4: 1-46; and An et al. , EMBO J. (1985) 4:277-284.
  • a plant to be infected is wounded, e.g. by cutting the plant wid a razor or puncturing the plant with a needle or rubbing the plant with an abrasive.
  • the wound is then inoculated with the Agrobacterium.
  • the inoculated plant or plant part is then grown on a suitable culture medium and allowed to develop into mature plants.
  • tissue culturing methods such as by culturing the cells in a suitable culture medium supplied with the necessary growth factors such as amino acids, plant hormones, vitamins, etc.
  • Regeneration of the transformed cells into genetically modified plants may be accomplished using known methods for the regeneration of plants from cell or tissue cultures, for example by selecting transformed shoots using an antibiotic and by subculturing the shoots on a medium containing the appropriate nutrients, plant hormones, etc.
  • the present invention provides an arabinofuranosidase enzyme having arabinoxylan degrading activity and die nucleotide sequence coding for the same.
  • it provides a promoter that can control the expression of that, or another, nucleotide sequence.
  • it includes terminator and signal sequences for the same.
  • NCIMB National Collections of Industrial and Marine Bacteria Limited
  • the deposit number is NCIMB 40703.
  • Figures 1-10 are sequences of promoters and GOIs of earlier patent applications that are useful for use with the aspects of the present invention
  • Figure 11 is a plasmid map of the plasmid pB53.1 , which is the subject of deposit NCIMB 40703;
  • Figure 12 is a schematic diagram of deletions made to the promoter of the present invention.
  • Figure 13 is a plasmid map of pXP-AMY
  • Figure 14 is a plasmid map of pXP-XssAMY
  • Figure 15 is a graph
  • Figure 16 is an HP-TLC profile
  • Figure 17 is an HP-TLC profile
  • Figure 18 is an HPLC profile
  • Figure 19 is a viscosity plot
  • Figure 20 is an activity plot
  • Figure 21 is an activity plot
  • Figure 22 is an activity plot.
  • the enzyme of the present invention is sometimes referred to as AbfC.
  • the promoter of the present invention is sometimes referred to as the AbfC promoter.
  • Aspergillus niger 3M43 was grown in medium containing wheat bran and beet pulp. The fermentation broth was separated from the solid part of the broth by filtration. Concentrated fermentation broth was loaded on a 25X 100mm Q-SEPHAROSE (Pharmacia) high Performance column, equilibrated with 20 mM Tris, HCI pH 7.5, and a linear gradient from 0-500 Mm NaCl was performed and fractions of the eluate was collected. The Arabinofuranosidase was eluted at 130-150 Mm NaCl.
  • the enzyme was concentrated using High-Trap spin columns. Next the concentrated and desalted fractions were subjected to gel filtration on a 50x600 mm SUPERDEX 50 column. The sample was loaded and the column was eluted widi 0.2 M Phosphate buffer pH 7.0 plus 0.2 M NaCl, and fractions of the eluate were collected.
  • the fractions containing arabinofuranosidase were combined and desalted and concentrated as described above.
  • the combined fractions were loaded on a 16X100 mm Phenylsepharose High Performance column (Pharmacia), equilibrated with 50 mM Phosphate buffer pH 6.0, containing 1.5 M (NH 4 ) 2 SO 4 .
  • a gradient where the (NH 4 ) 2 SO 4 concentration was varied from 1.5 - 0 M was applied and e eluate collected in fractions.
  • the fractions containing Arabinofuranosidase were combined.
  • the purity of the arabinofuranosidase was evaluated by SDS-PAGE using the Phast system gel (Pharmacia). Characterization
  • the molecular weight of the purified arabinofuranosidase was determined by mass spectrometry using laser desorption technology. The MW of the arabinofuranosidase was found to be 33,270 D ⁇ 50 D.
  • the pi value was determined by use of a Broad pi Kit (Pharmacia).
  • the arabinofuranosidase has a pi value of about 3.7.
  • the effect of pH on the activity of the arabinofuranosidase of the present invention was investigated using water soluble pentosan (10 mg/ml) from wheat as a substrate in 50 mM citric acid sodium phosphate buffer. The incubation time was 15 minutes.
  • the arabinofuranosidase of the present invention was observed to have a wide pH optima range of from about 2.5 to about 7.0 (see Figure 20), more especially from about 3.3 to about 4.6, more especially about 4.
  • the effect of temperature on the activity of the arabinofuranosidase of the present invention was investigated using water soluble pentosan (10 mg/ml) from wheat as a substrate in 50 mM sodium acetate at a pH of 5.0.
  • the incubation time was 15 minutes.
  • the arabinofuranosidase of die present invention was observed to have an optimal activity at a temperature of from about 40°C to about 60°C, more especially from about 45°C to about 55°C, more especially about 50°C ( Figure 22).
  • the enzyme is still active at about 10°C and showed residual activity at 70°C and 80°C.
  • the enzyme was digested with endoproteinase Lys-C sequencing grade from Boehringer Mannheim using a modification of the method described by Stone & Williams 1993 (Stone, K.L. and Williams, K.R. (1993). Enzymatic digestion of Proteins and HPLC Peptide Isolation. In : Matsudaira P. (Editor). A practical Guide to Protein and Peptide Purification for Microsequencing. Second Edition. Academic Press, San Diego 1993. pp 45-73).
  • Freeze dried ⁇ -arabinofuranosidase (0.4 mg) was dissolved in 50 ⁇ l of 8M urea, 0.4 M NH 4 HCO 3 , pH 8.4. After overlay with N 2 and addition of 5 ⁇ l of 45 Mm DTT, the protein was denatured and reduced for 15 min at 50°C under N 2 . After cooling to RT, 5 ⁇ l of 100 Mm iodoacetamide was added for the cysteines to be derivatised for 15 min at RT in the dark under N 2 .
  • PCR primers were synthesised using an Applied Biosystems DNA synthesiser model 392.
  • PCR primers were synthesized from one of the found peptide sequences, namely SEQ ID No. 5.
  • the primers were:
  • PCR amplification was performed with 100 pmol of each of these primers in 100 ⁇ l reactions using Amplitaq polymerase (PERKIN ELMER). The following program was:
  • Steps 2-4 were repeated for 40 cycles. PCR reactions were performed on a PERKIN ELMER DNA Thermal Cycler.
  • a 100 bp amplified fragment was isolated and cloned into a pT7-Blue T-vector, according to the manufacturers instructions (Novagen).
  • isopropanol to precipitate the extracted DNA. After further centrifugation for 15 mins. the DNA pellet was dissolved in 0.7 ml TE (lOmM Tris, HCI pH 8.0, ImM EDTA) and precipitated with 75 ⁇ l 3M NaAc, pH 4.8, and 500 ⁇ l isopropanol.
  • TE lOmM Tris, HCI pH 8.0, ImM EDTA
  • SEQ. ID. No. 12 presents die promoter sequence, the enzyme coding sequence, die terminator sequence and d e signal sequence and die amino acid sequence of the enzyme of the present invention.
  • the samples were diluted 1 : 1 in water and analysed on a Chromopack Carbohydrate Pb column (300X7.8 mm, cat. 29010) using Shimadzu C-R4A Chromatopac HPLC system using a Shimadzu RI D-6A refractive index detector in accordance with the suppliers instructions.
  • the column was calibrated using a standard composed of 0.48 mg/ml xylotriose, 0.48 mg/ml xylobiose, 0.60 mg/ml xylose and 0.58 mg/ml L-arabinose.
  • the peaks were identified and quantified using die software supplied with the equipment.
  • abfC denotes the enzyme according to the present invention
  • xyl denotes the xylanase described before.
  • abfC denotes d e enzyme according to the present invention
  • xyl denotes the xylanase described before
  • Figure 17 shows HP-TLC profiles of the AbfC enzyme acting synergistically with Xylanase A.
  • WSP water-soluble pentosan
  • WIP water-insoluble pentosan
  • oat xylan as substrate.
  • the standards were: X- xylose; X 2 - xylobiose; X 3 - xylotriose; A- arabinose.
  • Figure 18 shows the HPLC analysis of hydrolysis products using 1 % oat spelt xylan as d e substrate.
  • Figure 18(a) and Figure 18(b) show the products when the AbfC enzyme and the xylanase enzyme respectively were used alone.
  • Figure 18(c) show the products when the AbfC enzyme and the xylanase enzyme when combined.
  • the enzyme of the present invention liberates arabinose, in particular L- arabinose, from arabinoxylan.
  • the combined actions of die enzyme according to die present invention with the endoxylanase is significantly higher than the sum of their individual action. Accordingly, the two enzymes affect each others enzymatic activities in a synergistic fashion.
  • the regulation of transcription of the AbfC encoding gene of Aspergillus niger was studied using a strain containing a fusion of the AbfC promoter to the j3-glucuronidase encoding gene (uid A) of E coli.
  • GUS producing transformants were grown on different carbon sources and assayed bodi qualitatively and quantitatively for the ability to hydrolyse p-nitrophenol glucuronide.
  • the AbfC promoter is strongly repressed by glucose and is dierefore under carbon catabolite repression.
  • the AbfC promoter of the present invention is regulated strongly by the intermediates in xylose metabolism.
  • the present invention also covers an arabinofuranosidase promoter wherein the promoter is inducible by an intermediate in xylose metabolism. Effects of different promoter deletions on the regulation of the expression of the AbfC gene
  • this region contains the CCAAT element and is a putative target for a general transcriptional activator.
  • This sequence is similar to the nuclear protein binding sites found in two starch inducible promoters: the Aspergillus niger glucoamylase gene and die Aspergillus oryzae amylase gene as well as the amdS gene of Aspergillus nidulans.
  • the mycelium is harvested using Miracloth paper and 3-4 g wet mycelium are transferred to a sterile petri dish with 10 ml STC (1.2 M sorbitol, 10 mM Tris Hcl pH 7,5, 50 Mm CaCl 2 ) with 75 mg lysing enzymes (Sigma L-2265) and 4500 units lyticase (Sigma L- 8012).
  • the mycelium is incubated with the enzyme until die mycelium is degraded and die protoplasts are released.
  • the degraded mycelium is then filtered through a sterile 60 ⁇ m mesh filter.
  • the protoplasts are harvested by centrifugation 10 min at 2000 rpm in a swing out rotor. The supernatant is discarded and the pellet is dissolved in 8 ml 1.5 M MgSO 4 , and d en centrifuged at 3000 rpm for 10 min.
  • the upper band, containing die protoplasts is transferred to another tube, using a transfer pipette and 2 ml 0.6 M KC1 is added. Carefully 5 ml 30% sucrose is added on the top and the tube is centrifuged 15 min at 3000 rpm.
  • the protoplasts, lying in the interface band, are transferred to a new tube and diluted with 1 vol. STC.
  • the solution is centrifuged 10 min at 3000 rpm.
  • the pellet is washed twice with STC, and finally solubilized in 1 ml STC.
  • the protoplasts are counted and eventually concentrated before transformation.
  • 100 ⁇ l protoplast solution (10 6 -10 7 protoplasts) are mixed with 10 ⁇ l DNA solution containing 5- 10 ⁇ g DNA and incubated 25 min at room temperature. Then 60 % PEG-4000 is carefully added in portions of 200 ⁇ l, 200 ⁇ and 800 ⁇ l. The mixture is incubated 20 min at room temperature. 3 ml STC is added to the mixture and carefully mixed. The mixture is centrifuged 3000 rpm for 10 min.
  • the supernatant is removed and the protoplasts are solubilized in the remaining of the supernatant.
  • 3-5 ml topagarose is added and the protoplasts are quickly spread on selective plates.
  • the expression vector pXP-Amy ( Figure 13) contains the 2.1 kb ⁇ -amylase encoding gene from Thermomyces lanuginosus cloned downstream of the AbfC promoter (2.1 kb) and upstream of the Xylanase A terminator. This vector together with the hygromycin gene as a selectable marker was used for co-transformation experiments to test the functionality of die AbfC promoter.
  • the substrate specificity of the purified AbfC was determined using arabinose containing hemicelluloses: arabinoxylans from wheat, oat and larch, branched and debranched arabinans; arabinogalactan, sugar beet pectin, and xyloglucan.
  • HPLC and HP-TLC results are shown in Figure 16, in which the following abbreviations are used: WSP - water-soluble pentosan, WIP - water-insoluble pentosan, AG - arabinogalactan, deB-A - debranched arabinan.
  • the standards used were: A- arabinose, X- xylose.
  • diat arabinose is the hydrolysis product from arabinoxylans. No hydrolysis products were released from arabinogalactan, debranched arabinan or xyloglucan. Arabinose was released as a hydrolysis product from branched arabinan.
  • AbfC is therefore a 1,2/1,2 debranching enzyme and it has no activity towards linear 1 ,5 ⁇ -linked L-arabinofuranose residues found in debranched arabinans and arabinogalactan. This enzyme also releases a product when pectin is used as the substrate. It is believed that diis product is an arabinose containing ferulic acid or an arabinobiose. Reduction of Viscosity By AbfC
  • the enzyme of the present invention could be used to reduce the viscosity of feeds.
  • the enzyme would reduce the viscosity of branched substrates by removing the branches but not the backbone of that substrate. This is in contrast to the known viscosity modifiers which degrade the substrate backbone.
  • the present invention covers a process of reducing the viscosity of a branched substrate wherein the enzyme degrades the branches of the substrate but not the backbone of the substrate.
  • the present invention covers the use of the enzyme of the present invention as a viscosity modifier.
  • the results show that the enzyme of the present invention can be used to reduce the viscosity of pectins, especially pectins that are used in beverages - such as fruit juices.
  • d e present invention covers the use of the enzyme of the present invention to reduce the viscosity of pectin.
  • Antibodies were raised against the enzyme of the present invention by injecting rabbits with the purified enzyme and isolating die immunoglobulins from antiserum according to procedures described according to N Harboe and A Ingild ("Immunization, Isolation of Immunoglobulins, Estimation of Antibody Titre" In A Manual of Quantitative Immunoelectrophoresis, Methods and Applications, N H Axelsen. et al (eds.), Universitetsforlaget, Oslo, 1973) and by T G Cooper ("The Tools of Biochemistry” , John Wiley & Sons, New York, 1977).
  • the present invention provides a novel and inventive arabinofuranosidase, as well as the coding sequence dierefor and the promoter for that sequence.
  • An important advantage of the present invention is that the enzyme can be produced in high amounts.
  • d e promoter and die regulatory sequences can be used to express or can be used in the expression of GOIs in organisms, such as in A. niger.
  • arabinofuranosidase of die present invention is different from the arabinofuranosidases previously known.
  • the previous described arabinofuranosidases - such as those of EP-A-0506190 - are characterised by their ability to degrade arabinan, and are assayed using p-nitrophenyl-arabinoside.
  • arabinofuranosidase of the present invention does not degrade arabinan, and only a minor activity is seen on p-nitrophenyl-arabinoside.
  • arabinofuranosidase of die present invention is useful for degrading arabinoxylan. Therefore, the arabinofuranosidase of the present invention is quite different from the previous isolated arabinofuranosidases.
  • the enzyme of the present invention is capable of specifically cleaving arabinose from the xylose backbone of arabinoxylan.
  • the enzyme of the present invention is useful as it can improve processes for preparing foodstuffs and feeds as well as die foodstuffs and feeds themselves.
  • the enzyme of the present invention may be added to animal feeds which are rich in arabinoxylans.
  • feeds including silage
  • monogastic animals e.g. poultry or swine
  • cereals such as barley, wheat, maize, rye or oats or cereal by-products such as wheat bran or maize bran
  • the enzyme significantly improves the break-down of plant cell walls which leads to better utilization of the plant nutrients by the animal.
  • arabinoxylan-degrading enzymes may be used to reduce the viscosity of feeds containing arabinans.
  • the arabinoxylan-degrading enzyme may be added beforehand to the feed or silage if pre-soaking or wet diets are preferred.
  • a possible further application for the enzyme according to d e present invention is in the pulp and paper industry.
  • the application of xylanases is often reported to be beneficial in the removal of lignins and terpenoids from the cellulose and hemicellulose residues of a hemicellulose backbone, an essential step in the processing of wood, wood pulp or wood derivative product for the production of paper.
  • the addition of arabinoxylan- degrading enzymes, produced according to the present invention, to the xylanase treatment step should assist in die degradation of an arabinan-containing hemicellulose backbone and thus facilitate an improved, more efficient removal of both lignins and terpenoids.
  • the application of arabinoxylan-degrading enzymes should be particularly advantageous in die processing of soft woods in which the hemicellulose backbone contains glucuronic acid.
  • the enzyme according to d e present invention is also useful as it acts in a synergistic manner with endoxylanase (see results presented above).
  • GTC TCT GAC GGC AAA CAT ATC GTC TAT GCG TCC ACT ACT GAT GAA GCG

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)

Abstract

An enzyme capable of degrading arabinoxylan is described. In addition, there is described a nucleotide sequence coding for the same and a promoter for controlling the expression of the same.

Description

ASPERGILLUS ARABINOFURANOSIDASE
The present invention relates to an enzyme. In addition, the present invention relates to a nucleotide sequence coding for the enzyme. Also, the present invention relates to a promoter, wherein the promoter can be used to control the expression of the nucleotide sequence coding for the enzyme.
In particular, the enzyme of the present invention is an arabinofuranosidase enzyme having arabinoxylan degrading activity.
It is known that it is desirable to direct expression of a gene of interest ("GOI") in certain tissues of an organism - such as a filamentous fungus (such as Aspergillus Niger) or'even a plant crop. The resultant protein or enzyme may be useful for the organism itself. For example, it may be desirable to produce crop protein products with an optimised amino acid composition and so increase the nutritive value of a crop. For example, the crop may be made more useful as a feed.
In the alternative, it may be desirable to isolate the resultant protein or enzyme and then use the protein or enzyme to prepare, for example, food compositions. In this regard, the resultant protein or enzyme can be a component of the food composition or it can be used to prepare food compositions, including altering the characteristics or appearance of food compositions. It may even be desirable to use the organism, such as a filamentous fungus or a crop plant, to express non-plant genes, such as for the same purposes.
Also, it may be desirable to use an organism, such as a filamentous fungus or a crop plant, to express mammalian genes. Examples of the latter products include interferons, insulin, blood factors and plasminogen activators. It is also desirable to use micro¬ organisms, such as filamentous fungi, to prepare products from GOIs by use of promoters that are active in the micro-organisms. Fruit and vegetable cell walls largely consist of polysaccharide, the major components being pectin, cellulose and xyloglucan (R.R. Selvendran and J.A. Robertson, IFR Report 1989). Numerous cell wall models have been proposed which attempt to incorporate the essential properties of strength and flexibility (P. Albersheim, Sci. Am. 232, 81-95, 1975; P. Albersheim, Plant Biochem. 3rd Edition (Bonner and Varner), Ac. Press, 1976; T. Hayashi, Ann. Rev. Plant Physiol. & Plant Mol. Biol. , 40, 139-168, 1989).
The composition of the plant cell wall is complex and variable. Polysaccharides are mainly found in the form of long chains of cellulose (the main structural component of the plant cell wall), hemicellulose (comprising various β-xylan chains) and pectic substances (consisting of galacturonans and rhamnogalacturonans; arabinans; and galactans and arabinogalactans). From the standpoint of the food industry, the pectic substances, arabinans in particular, have become one of the most important constituents of plant cell walls (Whitaker, J.R. (1984) Enzyme Microb. Technol. , 6,341).
One form of plant polysaccharide is arabinan. A review of arabinans may be found in EP-A-0506190. According to this document, arabinans consist of a main chain of α- (1→5) groups linked to one another. Side chains are linked -(l→3) or sometimes a- (l-*2) to the main -(l-*5)-L-arabinan backbone. In apple, for example, one third of the total arabinose is present in the side chains. The molecular weight of arabinan is normally about 15 kDa.
Arabinans are degraded by enzymes collectively called arabinases. In this regard, arabinan-degrading activity is the ability of an enzyme to release arabinose residues, either monomers or oligomers, from arabinan backbones or from arabinan-containing side chains of other hemicellulose backbone structures such as arabinogalactans, or even the release of arabinose monomers via the cleavage of the l-*6 linkage between the terminal arabinofuranosyl unit and the intermediate glucosyl unit of monoterpenyl α-L- arabinofuranosyl glucosides. The activity of the arabinan degrading enzymes of EP-A-0506190 include: a) the ability to cleave (l→2)-o_-L-arabinosidic linkages; b) the ability to cleave (l→3)-o.-L-arabinosidic linkages; c) the ability to cleave (l-»5)-α-L-arabinosidic linkages; d) the ability to cleave the 1→6 linkage between the terminal arabinofuranosyl unit and the intermediate glucosyl unit of monoterpenyl α-L-arabinofuranosyl glucosides.
Arabinan-degrading enzymes are known to be produced by a variety of plants and microorganisms, among these, fungi such as those of the genera Aspergillus, Corticiwn, Rhodotorula (Kaji, A. (1984) Adv. Carbohydr. Chem. Biochem. , 42, 383), Dichotomitus (Brillouet et al. (1985) Carbohydrate Research, 144, 113), Ascomycetes and Basidomycetes (Sydow, G. (1977) DDR Patent Application No. 124,812).
Another plant polysaccharide is xylan, whose major monosaccharide unit is xylose. Xylans are abundant components of the hemicelluloses. In monocotyledonous plants the dominant hemicellulose is an arabinoxylan, in which arabinose side chains are attached to a backbone of xylose residues.
Arabinoxylans are carbohydrates found in the cell wall of cereals. A review of arabinoxylans and the enzymatic degradation thereof may be found in Voragen et al (1992 Characterisation of Cereal Arabinoxylans, Xylans and Xylanases pages 51-67, edited by J. Visser published by Elsevier Science Publishers).
Typically, arabinoxylans comprise a xylose backbone linked together via 0-1 ,4- bonds. The xylose backbone is substituted with L-arabinose residues which are linked via -1 bonds to the 2 or 3 position of the xylose residues. The xylose residues can be single or double substituted. In addition to substitution with arabinose the xylose residues can be substituted with acetyl groups, glucuronic acid and various other carbohydrates. The arabinose residues can be further substituted with phenolic acids such as ferulic acid and coumaric acid. The degree and kind of substitution depends on the source of the particular arabinoxylan. Arabinoxylans are found in cereal cell wall where they are part of the secondary cell wall. Arabinoxylans form about 3 % of wheat flour - part of it is water soluble (WSP), pan of it is water insoluble (WIP) .
Despite the fact that the arabinoxylans amount to only about 3 % of wheat the importance of the arabinoxylan fraction is much higher. This is because the arabinoxylans of cereals act as hydrocoUoids, as they form a gel like structure with water. For example, the arabinoxylans of wheat flour bind up to 30% of the water in a dough despite the fact that they amount to only 3 % of the dry matter. When arabinoxylans bind water they increase the viscosity of the ground cereals and to such an extent that the cereals can become difficult to manage.
The rheological properties of several systems where ground cereals are used can be manipulated using enzymes that degrade arabinoxylans. In modern bakery it is advantageous to reduce the viscosity of the dough in order to reduce the energy needed to process the doughs and also to get a higher volume of the bread. This is usually achieved by using enzymes that can degrade the xylose backbone of arabinoxylans.
Enzymes that only cleave the arabinose side chains from the xylan backbone of arabinoxylan are, for the purposes of this application, collectively called arabinoxylan degrading enzymes.
In feeds based on cereals, arabinoxylans in the cereals can increase the viscosity of the fluids in the intestines of the animals after the feeds have been ingested. This is a problem as it causes discomfort, such as indigestion, to the animals. Also, the nutritive value of the feeds is reduced. These problems can be avoided by addition of enzymes that degrade the arabinoxylan (such as xylanases) to the feed to avoid indigestion and to increase the nutritive value of the feed. However, some enzymes that degrade the arabinoxylans (especially some of the xylanases) require the presence of unsubstituted backbones and so their activity can be limited. Further discussions on arabinoxylans can be found in Xylans and Xylanases (1992, edited by J. Visser published by Elsevier Science Publishers).
An arbinoxylan degrading enzyme is (l ,4)-β-D-arabinoxylan arabinofuranohydrolase (AXH), as described by Kormelink et al 1991 (Kormelink, F.J.M. , Searle-Van Leeuwen M.J.F. , Wood. T.M. , Voragen, A.G.J.(1991) Purification and characterization of a (1 ,4)-/3-D-arabinoxylan arabinofuranohydrolase from Aspergillus awamori. Appl. Micro- biol. Biotechnol. 25:753-758). However, this document provides no sequence data for the enzyme or the nucleotide sequence coding for same or for the promoter for the same.
Clearly, it would be useful to be able to degrade arabinoxylans, preferably by use of recombinant DNA techniques.
The present invention seeks to provide an enzyme having arabinoxylan degrading activity; preferably wherein the enzyme can be prepared in certain or specific cells or tissues, such as in just a specific cell or tissue, of an organism, typically a filamentous fungus, preferably of the genus Aspergillus, such as Aspergillus niger, or even a plant.
Also, the present invention seeks to provide a GOI coding for the enzyme that can be expressed preferably in specific cells or tissues, such as in certain or specific cells or tissues, of an organism, typically a filamentous fungus, preferably of the genus Aspergillus, such as Aspergillus niger, or even a plant.
In addition, the present invention seeks to provide a promoter that is capable of directing expression of a GOI, such as a nucleotide sequence coding for the enzyme according to the present invention, preferably in certain specific cells or tissues, such as in just a specific cell or tissue, of an organism, typically a filamentous fungus, preferably of the genus Aspergillus, such as Aspergillus niger, or even a plant. Preferably, the promoter is used in Aspergillus wherein the product encoded by the GOI is excreted from the host organism into the surrounding medium. Furthermore, the present invention seeks to provide constructs, vectors, plasmids, cells, tissues, organs and organisms comprising the GOI and/or the promoter, and methods of expressing the same, preferably in specific cells or tissues, such as expression in just a specific cell or tissue, of an organism, typically a filamentous fungus, preferably of the genus Aspergillus, or even a plant.
According to a first aspect of the present invention there is provided an enzyme obtainable from Aspergillus, wherein the enzyme has the following characteristics: a MW of 33,270 D ± 50 D; a pi value of about 3.7; arabinoxylan degrading activity; a pH optima of from about 2.5 to about 7.0 (more especially from about 3.3 to about 4.6, more especially about 4); a temperature optima of from about 40°C to about 60°C (more especially from about 45°C to about 55°C, more especially about 50°C); and wherein the enzyme is capable of cleaving arabinose from the xylose backbone of an arabinoxylan.
According to a second aspect of the present invention there is provided an enzyme having the sequence shown as SEQ. I.D. No. 1 or a variant, homologue or fragment thereof.
According to a third aspect of the present invention there is provided an enzyme coded by the nucleotide sequence shown as SEQ. I.D. No. 2 or a variant, homologue or fragment thereof or a sequence complementary thereto.
According to a fourth aspect of the present invention there is provided a nucleotide sequence coding for the enzyme according to the present invention.
According to a fifth aspect of the present invention there is provided a nucleotide sequence having die sequence shown as SEQ. I.D. No. 2 or a variant, homologue or fragment thereof or a sequence complementary thereto.
According to a sixth aspect of the present invention there is provided a promoter having the sequence shown as SEQ. I.D. No. 3 or a variant, homologue or fragment thereof or a sequence complementary thereto. According to a seventh aspect of the present invention there is provided a terminator having the nucleotide sequence shown as SEQ. I.D. No. 13 or a variant, homologue or fragment thereof or a sequence complementary thereto.
According to an eighth aspect of the present invention there is provided a signal sequence having the nucleotide sequence shown as SEQ. I.D. No. 14 or a variant, homologue or fragment thereof or a sequence complementary thereto.
According to a ninth aspect of the present invention there is provided a process for expressing a GOI by use of a promoter, wherein the promoter is the promoter according to the present invention.
According to a tenth aspect of the present invention there is provided the use of an enzyme according to the present invention to degrade an arabinoxylan.
According to an eleventh aspect of the present invention there is provided a combination of enzymes to degrade an arabinoxylan, the combination comprising an enzyme according to the present invention and a xylanase.
According to a twelfth aspect of the present invention there is provided plasmid NCIMB 40703, or a nucleotide sequence obtainable therefrom for expressing an enzyme capable of degrading arabinoxylan or for controlling the expression thereof or for controlling the expression of another GOI.
According to a thirteenth aspect of the present invention there is provided a signal sequence having the sequence shown as SEQ. I.D. No. 15 or a variant, homologue or fragment thereof.
According to a fourteenth aspect of the present invention there is provided the use of the enzyme according to the present invention in the manufacture of a medicament or foodstuff to reduce or prevent indigestion and/or increase digestibility and/or increase nutrient absorption. According to a fifteenth aspect of the present invention there is provided an arabinofuranosidase enzyme having arabinoxylan degrading activity, which is immunologicaily reactive with an antibody raised against a purified arabinofuranosidase enzyme having the sequence shown as SEQ. I.D. No. 1.
According to a sixteenth aspect of the present invention there is provided an arabinofuranosidase promoter wherein the promoter is inducible by an intermediate in xylose metabolism.
According to a seventeenth aspect of the present invention there is provided a process of reducing the viscosity of a branched substrate wherein the enzyme degrades the branches of the substrate but not the backbone of the substrate.
According to a further aspect of the present invention there is provided the use of the enzyme of the present invention as a viscosity modifier.
According to a further aspect of the present invention there is provided the use of the enzyme of the present invention to reduce the viscosity of pectin.
Other aspects of the present invention include constructs, vectors, plasmids, cells, tissues, organs and transgenic organisms comprising the aforementioned aspects of the present invention.
Other aspects of the present invention include methods of expressing or allowing expression or transforming any one of the nucleotide sequence, the construct, the plasmid, the vector, the cell, the tissue, the organ or the organism, as well as the products thereof.
Additional aspects of the present invention include uses of the promoter for expressing GOIs in culture media such as a broth or in a transgenic organism. Further aspects of the present invention include uses of the enzyme for preparing or treating foodstuffs, including animal feed.
Preferably the enzyme is coded by the nucleotide sequence shown as SEQ. I.D. No. 2 or a variant, homologue or fragment thereof or a sequence complementary thereto.
Preferably the nucleotide sequence has the sequence shown as SEQ. I.D. No. 2 or a variant, homologue or fragment thereof or a sequence complementary thereto.
Preferably the nucleotide sequence is operatively linked to a promoter.
Preferably the promoter comprises the sequence CCAAT.
Preferably the promoter is the promoter having the sequence shown as SEQ. I.D. No. 3 or a variant, homologue or fragment thereof or a sequence complementary thereto.
Preferably, the promoter comprises the 100 bps sequence from the Xma 111 to the BamHl sites.
Preferably the promoter of the present invention is operatively linked to a GOI.
Preferably the GOI comprises a nucleotide sequence according to the present invention.
Preferably the transgenic organism is a fungus.
Preferably the transgenic organism is a filamentous fungus, more preferably of the genus Aspergillus.
Preferably the transgenic organism is a plant.
Preferably, in the use, the enzyme is used in combination with a xylanase, preferably an endoxylanase. Highly preferred embodiments of each of the aspects of the present invention do not include any one of the native enzyme, the native promoter or the native nucleotide sequence in its natural environment.
Preferably, in any one of the plasmid, the vector such as an expression vector or a transformation vector, the cell, the tissue, the organ, the organism or the transgenic organism, the promoter is present in combination with at least one GOI.
Preferably the promoter and the GOI are stably incorporated within the transgenic organism's genome.
Preferably the transgenic organism is a filamentous fungus, preferably of the genus Aspergillus, more preferably Aspergillus niger. The transgenic organism can even be a plant, such as a monocot or dicot plant.
A highly preferred embodiment is an enzyme obtainable from Aspergillus, wherein the enzyme has the following characteristics: a MW of 33,270 D ± 50 D; a pi value of about 3.7; arabinoxylan degrading activity; a pH optima of from about 2.5 to about 7.0 (more especially from about 3.3 to about 4.6, more especially about 4); a temperature optima of from about 40°C to about 60°C (more especially from about 45°C to about 55°C, more especially about 50°C); and wherein the enzyme is capable of cleaving arabinose from the xylose backbone of an arabinoxylan; wherein the enzyme has the sequence shown as SEQ. I.D. No. 1 or a variant, homologue or fragment thereof.
Another highly preferred embodiment is an enzyme obtainable from Aspergillus, wherein the enzyme has the following characteristics: a MW of 33,270 D ± 50 D; a pi value of about 3.7; arabinoxylan degrading activity; a pH optima of from about 2.5 to about 7.0 (more especially from about 3.3 to about 4.6, more especially about 4); a temperature optima of from about 40°C to about 60°C (more especially from about 45°C to about 55°C, more especially about 50°C); and wherein the enzyme is capable of cleaving arabinose from the xylose backbone of an arabinoxylan; wherein the enzyme is coded by the nucleotide sequence shown as SEQ. I.D. No. 2 or a variant, homologue or fragment thereof or a sequence complementary thereto.
The advantages of the present invention are that it provides a means for preparing an arabinofuranosidase enzyme having arabinoxylan degrading activity and the nucleotide sequence coding for the same. In addition, it provides a promoter that can control the expression of that, or another, nucleotide sequence.
Other advantages are that the enzyme of the present invention can affect the viscosity of ground cereals, such as dough, to ease the handling thereof and for example to get a higher volume of the bread.
The enzyme of the present invention is also advantageous for feed because it degrades arabinoxylan and thus increases the nutritive value of the feed. In addition, it reduces the viscosity of the arabinoxylan in the intestine of the animals and so reduces or prevents indigestion.
The combination of the use of the enzyme of the present invention with a xylanase is particularly advantageous because the enzyme of the present invention and the xylanase have a surprising and unexpected synergistic effect with each other.
In this regard, the enzyme of the present invention increases the degradative effect of the xylanase, and the xylanase increases the degradative effect of the enzyme of the present invention. It is believed that the activity of the xylanase is increased because the enzyme of the present invention provides a polysaccharide substrate having fewer substituted groups.
The present invention therefore provides an enzyme having arabinoxylan degrading activity wherein the enzyme can be prepared in certain or specific cells or tissues, such as in just a specific cell or tissue, of an organism, typically a filamentous fungus, preferably of the genus Aspergillus, such as Aspergillus niger. The enzyme may even be prepared in a plant. More in particular, the enzyme of the present invention is capable of specifically cleaving arabinose from the xylose backbone of arabinoxylan.
The arabinofuranosidase of the present invention is different from the arabinofuranosidases previously known. In this regard, the previous described arabinofuranosidases - such as those of EP-A-0506190 - are characterised by their ability to degrade unbranched arabinan, and are assayed using p-nitrophenyl-arabinoside.
The arabinofuranosidase of the present invention does not degrade unbranched arabinan, and only a minor activity is seen on nitrophenyl-arabinoside. In contrast, the arabinofuranosidase of the present invention is useful for degrading arabinoxylan. Therefore, the arabinofuranosidase of the present invention is quite different from the previous isolated arabinofuranosidases.
Also, the present invention provides a GOI coding for the enzyme that can be expressed preferably in specific cells or tissues, such as in certain or specific cells or tissues, of an organism, typically a filamentous fungus, preferably of the genus Aspergillus, such as Aspergillus niger. The GOI may even be expressed in a plant.
In addition, the present invention provides a promoter that is capable of directing expression of a GOI, such as a nucleotide sequence coding for the enzyme according to the present invention, preferably in certain specific cells or tissues, such as in just a specific cell or tissue, of an organism, typically a filamentous fungus, preferably of the genus Aspergillus, such as Aspergillus niger, or even a plant. Preferably, the promoter is used in Aspergillus wherein the product encoded by the GOI is excreted from the host organism into the surrounding medium. The promoter may even be tailored (if necessary) to express a GOI in a plant.
The present invention also provides constructs, vectors, plasmids, cells, tissues, organs and organisms comprising the GOI and/or the promoter, and methods of expressing the same, preferably in specific cells or tissues, such as expression in just a specific cell or tissue, of an organism, typically a filamentous fungus, preferably of the genus Aspergillus, or even a plant.
The terms "variant" , "homologue" or "fragment" in relation to the enzyme include any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) amino acid from or to the sequence providing the resultant amino acid sequence has arabinoxylan degrading activity, preferably having at least the same activity of the enzyme shown in the sequence listings (SEQ I.D. No. 1 or 12). In particular, the term "homologue" covers homology with respect to structure and/or function providing the resultant enzyme has arabinoxylan degrading activity. With respect to sequence homology, preferably there is at least 75%, more preferably at least 85% , more preferably at least 90% homology to SEQ ID NO. 1 shown in the attached sequence listings. More preferably there is at least 95%, more preferably at least 98%, homology to SEQ ID NO. 1 shown in the attached sequence listings.
The terms "variant", "homologue" or "fragment" in relation to the nucleotide sequence coding for the enzyme include any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) nucleic acid from or to the sequence providing the resultant nucleotide sequence codes for an enzyme having arabinoxylan degrading activity, preferably having at least the same activity of the enzyme shown in the sequence listings (SEQ I.D. No. 2 or 12). In particular, the term "homologue" covers homology with respect to structure and/or function providing the resultant nucleotide sequence codes for an enzyme having arabinoxylan degrading activity. With respect to sequence homology, preferably there is at least 75 %, more preferably at least 85%, more preferably at least 90% homology to SEQ ID NO. 2 shown in the attached sequence listings. More preferably there is at least 95%, more preferably at least 98%, homology to SEQ ID NO. 2 shown in the attached sequence listings.
The terms "variant", "homologue" or "fragment" in relation to the promoter include any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) nucleic acid from or to the sequence providing the resultant nucleotide sequence has the ability to act as a promoter in an expression system - such as the transformed cell or the transgenic organism according to the present invention. In paπicular, the term "homologue" covers homology with respect to structure and/or function providing the resultant nucleotide sequence has the ability to act as a promoter. With respect to sequence homology, preferably there is at least 75 % , more preferably at least 85 % , more preferably at least 90% homology to SEQ ID NO. 3 shown in the attached sequence listings. More preferably there is at least 95% , more preferably at least 98%, homology to SEQ ID NO. 3 shown in the attached sequence listings.
The terms "variant" , "homologue" or "fragment" in relation to the terminator or signal nucleotide sequences include any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) nucleic acid from or to the sequence providing the resultant nucleotide sequence has the ability to act as a terminator or codes for an amino acid sequence that has the ability to act as a signal sequence respectively in an expression system - such as the transformed cell or the transgenic organism according to the present invention. In particular, the term "homologue" covers homology with respect to structure and/or function providing the resultant nucleotide sequence has the ability to act as or code for a terminator or signal respectively. With respect to sequence homology, preferably there is at least 75%, more preferably at least 85 %, more preferably at least 90% homology to SEQ ID NO.s 13 and 14 (respectively) shown in the attached sequence listings. More preferably there is at least 95 % , more preferably at least 98%, homology to SEQ ID NO.s 13 and 14 (respectively) shown in the attached sequence listings.
The terms "variant" , "homologue" or "fragment" in relation to the signal amino acid sequence include any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) amino acid from or to the sequence providing the resultant sequence has the ability to act as a signal sequence in an expression system - such as the transformed cell or the transgenic organism according to the present invention. In particular, the term "homologue" covers homology with respect to structure and/or function providing the resultant nucleotide sequence has the ability to act as or code for a signal respectively. With respect to sequence homology, preferably there is at least 75%, more preferably at least 85%, more preferably at least 90% homology to SEQ ID NO 15 shown in the attached sequence listings. More preferably there is at least 95 %, more preferably at least 98%, homology to SEQ ID NO 15 shown in the attached sequence listings.
The above terms are synonymous with allelic variations of the sequences.
The term "complementary" means that the present invention also covers nucleotide sequences that can hybridise to the nucleotide sequences of the coding sequence or the promoter sequence, respectively.
The term "nucleotide" in relation to the present invention includes genomic DNA, cDNA, synthetic DNA, and RNA. Preferably it means DNA, more preferably cDNA for the coding sequence of the present invention.
The term "construct" - which is synonymous with terms such as "conjugate" , "cassette" and "hybrid" - includes a GOI directly or indirectly attached to a promoter. An example of an indirect attachment is the provision of a suitable spacer group such as an intron sequence, such as the SAi-intron or the ADH intron, intermediate the promoter and the GOI. The same is true for the term "fused" in relation to the present invention which includes direct or indirect attachment. In each case, it is highly preferred that the terms do not cover the natural combination of the gene coding for the enzyme ordinarily associated with the wild type gene promoter and when they are both in their natural environment. A highly preferred embodiment is the or a GOI being operatively linked to a or the promoter.
The construct may even contain or express a marker which allows for the selection of the genetic construct in, for example, a filamentous fungus, preferably of the genus Aspergillus, such as Aspergillus niger, or plants, preferably cereals, such as maize, rice, barley etc. , into which it has been transferred. Various markers exist which may be used, such as for example those encoding mannose-6-phosphate isomerase (especially for plants) or those markers that provide for antibiotic resistance - e.g. resistance to G418, hygromycin, bleomycin, kanamycin and gentamycin. The term "vector" includes expression vectors and transformation vectors.
The term "expression vector" means a construct capable of in vivo or in vitro expression.
The term "transformation vector" means a construct capable of being transferred from one species to another - such as from an E.coli plasmid to a filamentous fungus, preferably of the genus Aspergillus. It may even be a construct capable of being transferred from an E.coli plasmid to an Agrobacterium to a plant.
The term "tissue" includes tissue per se and organ.
The term "organism" in relation to the present invention includes any organism that could comprise the promoter according to the present invention and/or the nucleotide sequence coding for the enzyme according to the present invention and/or products obtained therefrom, wherein the promoter can allow expression of a GOI and/or wherein the nucleotide sequence according to the present invention can be expressed when present in the organism.
Preferably the organism is a filamentous fungus, preferably of the genus Aspergillus, more preferably Aspergillus niger.
The term "transgenic organism" in relation to the present invention includes any organism that comprises the promoter according to the present invention and/or the nucleotide sequence coding for the enzyme according to the present invention and/or products obtained therefrom, wherein the promoter can allow expression of a GOI and/or wherein the nucleotide sequence according to the present invention can be expressed within the organism. Preferably the promoter and/or the nucleotide sequence is (are) incorporated in the genome of the organism.
Preferably the transgenic organism is a filamentous fungus, preferably of the genus Aspergillus, more preferably Aspergillus niger. Therefore, the transgenic organism of the present invention includes an organism comprising any one of, or combinations of, the promoter according to the present invention, the nucleotide sequence coding for the enzyme according to the present invention, constructs according to the present invention, vectors according to the present invention, plasmids according to the present invention, cells according to the present invention, tissues according to the present invention or the products thereof. For example the transgenic organism can comprise a GOI, preferably an exogenous nucleotide sequence, under the control of the promoter according to the present invention. The transgenic organism can also comprise the nucleotide sequence coding for the enzyme of the present invention under the control of a promoter, which may be the promoter according to the present invention.
In a highly preferred embodiment, the transgenic organism does not comprise the combination of the promoter according to the present invention and the nucleotide sequence coding for the enzyme according to the present invention, wherein both the promoter and the nucleotide sequence are native to that organism and are in their natural environment. Thus, in these highly preferred embodiments, the present invention does not cover the native nucleotide coding sequence according to the present invention in its natural environment when it is under the control of its native promoter which is also in its natural environment. In addition, in this highly preferred embodiment, the present invention does not cover the native enzyme according to the present invention when it is in its natural environment and when it has been expressed by its native nucleotide coding sequence which is also in its natural environment and when that nucleotide sequence is under the control of its native promoter which is also in its natural environment.
The term "promoter" is used in the normal sense of the art, e.g. an RNA polymerase binding site in the Jacob-Mond theory of gene expression.
In one aspect, the promoter of the present invention is capable of expressing a GOI, which can be the nucleotide sequence coding for the enzyme of the present invention. In another aspect, the nucleotide sequence according to the present invention is under the control of a promoter that allows expression of the nucleotide sequence. In this regard, the promoter need not necessarily be the same promoter as that of the present invention. In this aspect, the promoter may be a cell or tissue specific promoter. If, for example, the organism is a plant then the promoter can be one that affects expression of the nucleotide sequence in any one or more of stem, sprout, root and leaf tissues.
By way of example, the promoter for the nucleotide sequence of the present invention can be the α-Amy 1 promoter (otherwise known as the Amy 1 promoter, the Amy 637 promoter or the α-Amy 637 promoter) as described in our co-pending UK patent application No. 9421292.5 filed 21 October 1994. That promoter comprises the sequence shown in Figure 1.
Alternatively, the promoter for the nucleotide sequence of the present invention can be the α-Amy 3 promoter (otherwise known as the Amy 3 promoter, the Amy 351 promoter or the α-Amy 351 promoter) as described in our co-pending UK patent application No. 9421286.7 filed 21 October 1994. That promoter comprises the sequence shown in Figure 2.
Preferably, the promoter is the promoter of the present invention.
In addition to the nucleotide sequences described above, the promoters, particularly that of the present invention, could additionally include features to ensure or to increase expression in a suitable host. For example, the features can be conserved regions such as a Pribnow Box or a TATA box. The promoters may even contain other sequences to affect (such as to maintain, enhance, decrease) the levels of expression of the GOI. For example, suitable other sequences include the SΛi-intron or an ADH intron. Other sequences include inducible elements - such as temperature, chemical, light or stress inducible elements.
Also, suitable elements to enhance transcription or translation may be present. An example of the latter element is the TMV 5' signal sequence (see Sleat Gene 217 [1987] 217-225; and Dawson Plant Mol. Biol. 23 [1993] 97).
In addition the present invention also encompasses combinations of promoters and/or nucleotide sequences coding for proteins or enzymes and/or elements. For example, the present invention encompasses the combination of a promoter according to the present invention operatively linked to a GOI, which could be a nucleotide sequence according to the present invention, and another promoter such as a tissue specific promoter operatively linked to the same or a different GOI.
The present invention also encompasses the use of promoters to express a nucleotide sequence coding for the enzyme according to the present invention, wherein a part of the promoter is inactivated but wherein the promoter can still function as a promoter. Partial inactivation of a promoter in some instances is advantageous.
In particular, with the Amy 351 promoter mentioned earlier it is possible to inactivate a part of it so that the partially inactivated promoter expresses GOIs in a more specific manner such as in just one specific tissue type or organ.
The term "inactivated" means partial inactivation in the sense that the expression pattern of the promoter is modified but wherein the partially inactivated promoter still functions as a promoter. However, as mentioned above, the modified promoter is capable of expressing a GOI in at least one (but not all) specific tissue of the original promoter. One such promoter is the Amy 351 promoter described above.
Examples of partial inactivation include altering the folding pattern of the promoter sequence, or binding species to parts of the nucleotide sequence, so that a part of the nucleotide sequence is not recognised by, for example, RNA polymerase. Another, and preferable, way of partially inactivating the promoter is to truncate it to form fragments thereof. Another way would be to mutate at least a part of the sequence so that the RNA polymerase can not bind to that part or another part. Another modification is to mutate the binding sites for regulatory proteins for example the CreA protein known from filamentous fungi to exert carbon catabolite repression, and thus abolish the catabolite repression of the native promoter.
The term "GOI" with reference to the present invention means any gene of interest. A GOI can be any nucleotide that is either foreign or natural to the organism (e.g. filamentous fungus, preferably of the genus Aspergillus, or a plant) in question. Typical examples of a GOI include genes encoding for proteins and enzymes that modify metabolic and catabolic processes. The GOI may code for an agent for introducing or increasing pathogen resistance. The GOI may even be an antisense construct for modifying the expression of natural transcripts present in the relevant tissues. The GOI may even code for a non- natural protein of a filamentous fungus, preferably of the genus Aspergillus, or a compound that is of benefit to animals or humans.
For example, the GOI could code for a pharmaceutically active protein or enzyme such as any one of the therapeutic compounds insulin, interferon, human serum albumin, human growth factor and blood clotting factors. In this regard, the transformed cell or organism could prepare acceptable quantities of the desired compound which would be easily retrievable from, the cell or organism. The GOI may even be a protein giving nutritional value to a food or crop. Typical examples include plant proteins that can inhibit the formation of anti-nutritive factors and plant proteins that have a more desirable amino acid composition (e.g. a higher lysine content than a non-transgenic plant). The GOI may even code for an enzyme that can be used in food processing such as chymosin, thaumatin and α-galactosidase. The GOI can be a gene encoding for any one of a pest toxin, an antisense transcript such as that for patatin or α-amylase, ADP-glucose pyrophosphorylase (e.g. see EP-A-0455316), a protease antisense or a glucanase.
The GOI can be the nucleotide sequence coding for the α-amylase enzyme which is the subject of our co-pending UK patent application 9413439.2 filed on 4 July 1994, d e sequence of which is shown in Figure 3. The GOI can be the nucleotide sequence coding for the α-amylase enzyme which is the subject of our co-pending UK patent application 9421290.9 filed on 21 October 1994, the sequence of which is shown in Figure 4. The GOI can be any of the nucleotide sequences coding for the ADP-glucose pyrophosphorylase enzymes which are the subject of our co-pending PCT patent application PCT/EP94/01082 filed 7 April 1994, the sequences of which are shown in Figures 5 and 6. The GOI can be any of the nucleotide sequences coding for the α- glucan lyase enzyme which are described in our co-pending PCT patent application PCT/EP94/03397 filed 15 October 1994, the sequences of which are shown in Figures 7-10.
In one preferred embodiment, the GOI is a nucleotide sequence coding for the enzyme according to the present invention.
As mentioned above, a preferred host organism is of the genus Aspergillus, such as Aspergillus niger. The transgenic Aspergillus according to the present invention can be prepared by following the teachings of Rambosek . and Leach, J. 1987 (Recombinant DNA in filamentous fungi: Progress and Prospects. CRC Crit. Rev. Biotechnol. 6:357- 393), Davis R.W. 1994 (Heterologous gene expression and protein secretion in Asperg¬ illus. In: Martinelli S.D., Kinghorn J.R.( Editors) Aspergillus: 50 years on. Progress in industrial microbiology voi 29. Elsevier Amsterdam 1994. pp 525-560), Ballance,D.J. 1991 (Transformation systems for Filamentous Fungi and an Overview of Fungal Gene structure. In :Leong,S.A. , Berka R.M. (Editors) Molecular Industrial Mycology. Systems and Applications for Filamentous Fungi. Marcel Dekker Inc. New York 1991. pp 1-29) and Turner G. 1994 (Vectors for genetic manipulation. In: Martinelli S.D. , Kinghorn J.R.( Editors) Aspergillus: 50 years on. Progress in industrial microbiology voi 29. Elsevier Amsterdam 1994. pp. 641-666). However, the following commentary provides a summary of those teachings for producing transgenic Aspergillus according to the present invention.
Filamentous fungi have during almost a century been widely used in industry for produc¬ tion of organic compounds and enzymes. Traditional Japanese koji and soy fermentations have used Aspergillus sp for hundreds of years. In this century Aspergillus niger has been used for production of organic acids particular citric acid and for production of various enzymes for use in industry. There are two major reasons for that filamentous fungi have been so widely used in industry. First filamentous fungi can produce high amounts of extracellular products, for example enzymes and organic compounds such as antibiotics or organic acids. Second filamentous fungi can grow on low cost substrates such as grains, bran, beet pulp etc. The same reasons have made filamentous fungi attractive organisms as hosts for heterologous expression according to the present invention.
In order to prepare the transgenic Aspergillus, expression constructs are prepared by inserting a GOI (such as an amylase or SEQ. I.D. No. 2) into a construct designed for expression in filamentous fungi.
Several types of constructs used for heterologous expression have been developed. The constructs contain the promoter according to the present invention (or if desired another promoter if the GOI codes for the enzyme according to the present invention) which is active in fungi. Examples of promoters other than that of the present invention include a fungal promoter for a highly expressed extracellular enzyme, such as the glucoamylase promoter or the α-amylase promoter. The GOI can be fused to a signal sequence (such as that of the present invention or another suitable sequence) which directs the protein encoded by the GOI to be secreted. Usually a signal sequence of fungal origin is used, such as diat of the present invention. A terminator active in fungi ends the expression system, such as that of the present invention.
Another type of expression system has been developed in fungi where the GOI is fused to a smaller or a larger part of a fungal gene encoding a stable protein. This can stabilize the protein encoded by the GOI. In such a system a cleavage site, recognized by a specific protease, can be introduced between the fungal protein and the protein encoded by the GOI, so the produced fusion protein can be cleaved at this position by the specific protease thus liberating the protein encoded by the GOI ("POI"). By way of example, one can introduce a site which is recognized by a KEX-2 like peptidase found in at least some Aspergilli. Such a fusion leads to cleavage in vivo resulting in protection of the POI and production of POI and not a larger fusion protein. Heterologous expression in Aspergillus has been reported for several genes coding for bacterial, fungal, vertebrate and plant proteins. The proteins can be deposited intracellularly if the GOI is not fused to a signal sequence. Such proteins will accumulate in the cytoplasm and will usually not be glycosylated which can be an advantage for some bacterial proteins. If the GOI is equipped with a signal sequence the protein will accumulate extracellulary.
With regard to product stability and host strain modifications, some heterologous proteins are not very stable when they are secreted into the culture fluid of fungi. Most fungi produce several extracellular proteases which degrade heterologous proteins. To avoid this problem special fungal strains with reduced protease production have been used as host for heterologous production.
For the transformation of filamentous fungi, several transformation protocols have been developed for many filamentous fungi (Ballance 1991, ibid). Many of them are based on preparation of protoplasts and introduction of DNA into the protoplasts using PEG and Ca2+ ions. The transformed protoplasts then regenerate and the transformed fungi are selected using various selective markers. Among the markers used for transformation are a number of auxotrophic markers such as argB, ϊrpC, niaD and pyrG, antibiotic resistance markers such as benomyl resistance, hygromycin resistance and phleomycin resistance. A very common used transformation marker is the amdS gene of A. nidulans which in high copy number allows the fungus to grow with acrylamide as the sole nitrogen source.
Even though the enzyme, the nucleotide sequence coding for same and the promoter of the present invention are not disclosed in EP-B-0470145 and CA-A-2006454, those two documents do provide some useful background commentary on the types of techniques that may be employed to prepare transgenic plants according to the present invention. Some of these background teachings are now included in die following commentary.
The basic principle in the construction of genetically modified plants is to insert genetic information in the plant genome so as to obtain a stable maintenance of the inserted genetic material.
Several techniques exist for inserting the genetic information, the two main principles being direct introduction of the genetic information and introduction of the genetic information by use of a vector system. A review of the general techniques may be found in articles by Potrykus (Annu Rev Plant Physiol Plant Mol Biol [1991] 42:205-225) and Christou (Agro-Food-Industry Hi-Tech March/ April 1994 17-27).
Thus, in one aspect, the present invention relates to a vector system which carries a promoter or nucleotide sequence or construct according to the present invention and which is capable of introducing the promoter or nucleotide sequence or construct into the genome of an organism, such as a plant.
The vector system may comprise one vector, but it can comprise two vectors. In the case of two vectors, the vector system is normally referred to as a binary vector system. Binary vector systems are described in further detail in Gynheung An et al. (1980), Binary Vectors, Plant Molecular Biology Manual A3, 1-19.
One extensively employed system for transformation of plant cells with a given promoter or nucleotide sequence or construct is based on the use of a Ti plasmid from Agrobacteήum tumefaciens or a Ri plasmid from Agrobacteήum rhizogenes An et al. (1986), Plant Physiol. 81 , 301-305 and Butcher D.N. et al. (1980), Tissue Culture Methods for Plant Pathologists, eds. : D.S. Ingrams and J.P. Helgeson, 203-208.
Several different Ti and Ri plasmids have been constructed which are suitable for the construction of the plant or plant cell constructs described above. A non-limiting example of such a Ti plasmid is pGV3850.
The promoter or nucleotide sequence or construct of the present invention should preferably be inserted into the Ti-plasmid between the terminal sequences of the T-DNA or adjacent a T-DNA sequence so as to avoid disruption of the sequences immediately surrounding the T-DNA borders, as at least one of these regions appear to be essential for insertion of modified T-DNA into the plant genome.
As will be understood from the above explanation, if the organism is a plant, then the vector system of the present invention is preferably one which contains the sequences necessary to infect the plant (e.g. the vir region) and at least one border pan of a T-DNA sequence, the border part being located on the same vector as the genetic construct.
Furthermore, the vector system is preferably an Agrobacteήum tumefaciens Ti-plasmid or an Agrobacterium rhizogenes Ri-plasmid or a derivative thereof, as these plasmids are well-known and widely employed in the construction of transgenic plants, many vector systems exist which are based on these plasmids or derivatives thereof.
In the construction of a transgenic plant the promoter or nucleotide sequence or construct of die present invention may be first constructed in a microorganism in which the vector can replicate and which is easy to manipulate before insertion into the plant. An example of a useful microorganism is E. coli, but other microorganisms having the above properties may be used. When a vector of a vector system as defined above has been constructed in £. coli, it is transferred, if necessary, into a suitable Agrobacterium strain, e.g. Agrobacterium tumefaciens. The Ti-plasmid harbouring the promoter or nucleotide sequence or construct of the invention is thus preferably transferred into a suitable Agrobacteήum strain, e.g. A. tumefaciens, so as to obtain an Agrobacteήum cell harbouring the promoter or nucleotide sequence or construct of the invention, which DNA is subsequently transferred into the plant cell to be modified.
As reported in CA-A-2006454, a large amount of cloning vectors are available which contain a replication system in E. coli and a marker which allows a selection of the transformed cells. The vectors contain for example pBR 322, pUC series, Ml 3 mp series, pACYC 184 etc.
In this way, the nucleotide or construct or promoter of the present invention can be introduced into a suitable restriction position in the vector. The contained plasmid is used for the transformation in E. coli. The E. coli cells are cultivated in a suitable nutrient medium and then harvested and lysed. The plasmid is then recovered. As a method of analysis there is generally used sequence analysis, restriction analysis, electrophoresis and further biochemical-molecular biological methods. After each manipulation, the used DNA sequence can be restricted and connected with the next DNA sequence. Each sequence can be cloned in die same or different plasmid.
After each introduction method of the desired promoter or construct or nucleotide sequence according to the present invention in the plants the presence and/or insertion of further DNA sequences may be necessary. If, for example, for the transformation the Ti- or Ri-plasmid of the plant cells is used, at least die right boundary and often however the right and the left boundary of the Ti- and Ri-plasmid T-DNA, as flanking areas of the introduced genes, can be connected. The use of T-DNA for the transformatron of plant cells has been intensively studied and is described in EP-A-120516; Hoekema, in: The Binary Plant Vector System Offset-drukkerij Kanters B.B. , Alblasserdam, 1985, Chapter V; Fraley, et al. , Crit. Rev. Plant Sci. , 4: 1-46; and An et al. , EMBO J. (1985) 4:277-284.
Direct infection of plant tissues by Agrobacterium is a simple technique which has been widely employed and which is described in Butcher D.N. et al. (1980), Tissue Culture Methods for Plant Pathologists, eds. : D.S. Ingrams and J.P. Helgeson, 203-208. For further teachings on this topic see Potrykus (Annu Rev Plant Physiol Plant Mol Biol [1991] 42:205-225) and Christou (Agro-Food-Industry Hi-Tech March/ April 1994 17-27). With this technique, infection of a plant may be done on a certain part or tissue of the plant, i.e. on a part of a leaf, a root, a stem or another part of the plant.
Typically, with direct infection of plant tissues by Agrobacterium carrying the promoter and/or the GOI, a plant to be infected is wounded, e.g. by cutting the plant wid a razor or puncturing the plant with a needle or rubbing the plant with an abrasive. The wound is then inoculated with the Agrobacterium. The inoculated plant or plant part is then grown on a suitable culture medium and allowed to develop into mature plants. When plant cells are constructed, these cells may be grown and maintained in accordance with well-known tissue culturing methods such as by culturing the cells in a suitable culture medium supplied with the necessary growth factors such as amino acids, plant hormones, vitamins, etc.
Regeneration of the transformed cells into genetically modified plants may be accomplished using known methods for the regeneration of plants from cell or tissue cultures, for example by selecting transformed shoots using an antibiotic and by subculturing the shoots on a medium containing the appropriate nutrients, plant hormones, etc.
Further teachings on plant transformation may be found in EP-A-0449375.
In summation, the present invention provides an arabinofuranosidase enzyme having arabinoxylan degrading activity and die nucleotide sequence coding for the same. In addition, it provides a promoter that can control the expression of that, or another, nucleotide sequence. In addition it includes terminator and signal sequences for the same.
The following sample was deposited in accordance with the Budapest Treaty at the recognised depositary The National Collections of Industrial and Marine Bacteria Limited (NCIMB) at 23 St. Machar Drive, Aberdeen, Scotland, United Kingdom, AB2 1RY on 16 January 1995:
E.coli containing plasmid pB53.1 {i.e. E.coli DH5α- pB53.1} . The deposit number is NCIMB 40703.
The present invention will now be described by way of example.
In the following Examples reference is made to the accompanying figures in which: Figures 1-10 are sequences of promoters and GOIs of earlier patent applications that are useful for use with the aspects of the present invention;
Figure 11 is a plasmid map of the plasmid pB53.1 , which is the subject of deposit NCIMB 40703;
Figure 12 is a schematic diagram of deletions made to the promoter of the present invention;
Figure 13 is a plasmid map of pXP-AMY;
Figure 14 is a plasmid map of pXP-XssAMY;
Figure 15 is a graph;
Figure 16 is an HP-TLC profile;
Figure 17 is an HP-TLC profile;
Figure 18 is an HPLC profile;
Figure 19 is a viscosity plot;
Figure 20 is an activity plot;
Figure 21 is an activity plot; and
Figure 22 is an activity plot.
The following text discusses the use of inter alia recombinant DNA techniques. General teachings of recombinant DNA techniques may be found in Sambrook, J. , Fritsch, E.F. , Maniatis T. (Editors) Molecular Cloning. A laboratory manual. Second edition. Cold Spring Harbour Laboratory Press. New York 1989.
In these Examples, the enzyme of the present invention is sometimes referred to as AbfC. In addition, the promoter of the present invention is sometimes referred to as the AbfC promoter.
Purification of the arabinofuranosidase
Aspergillus niger 3M43 was grown in medium containing wheat bran and beet pulp. The fermentation broth was separated from the solid part of the broth by filtration. Concentrated fermentation broth was loaded on a 25X 100mm Q-SEPHAROSE (Pharmacia) high Performance column, equilibrated with 20 mM Tris, HCI pH 7.5, and a linear gradient from 0-500 Mm NaCl was performed and fractions of the eluate was collected. The Arabinofuranosidase was eluted at 130-150 Mm NaCl.
The fractions containing the arabinofuranosidase were combined and desalted using a 50x200 mm G-25 SEPHAROSE Superfine (Pharmacia). The column was eluted with distilled water.
After desalting the enzyme was concentrated using High-Trap spin columns. Next the concentrated and desalted fractions were subjected to gel filtration on a 50x600 mm SUPERDEX 50 column. The sample was loaded and the column was eluted widi 0.2 M Phosphate buffer pH 7.0 plus 0.2 M NaCl, and fractions of the eluate were collected.
The fractions containing arabinofuranosidase were combined and desalted and concentrated as described above. The combined fractions were loaded on a 16X100 mm Phenylsepharose High Performance column (Pharmacia), equilibrated with 50 mM Phosphate buffer pH 6.0, containing 1.5 M (NH4)2SO4. A gradient where the (NH4)2SO4 concentration was varied from 1.5 - 0 M was applied and e eluate collected in fractions. The fractions containing Arabinofuranosidase were combined. The purity of the arabinofuranosidase was evaluated by SDS-PAGE using the Phast system gel (Pharmacia). Characterization
The molecular weight of the purified arabinofuranosidase was determined by mass spectrometry using laser desorption technology. The MW of the arabinofuranosidase was found to be 33,270 D ± 50 D.
The pi value was determined by use of a Broad pi Kit (Pharmacia). The arabinofuranosidase has a pi value of about 3.7.
After SDS-PAGE analysis, treatment PAS reagent showed that the arabinofuranosidase was glycosylated. The PAS staining was done according to the procedure of I. Van- Seuningen and M. Davril (1992) Electrophoresis 13 pp 97-99. Activity Studies
Activity of AbfC as a function of water soluble pentosan (WSP) concentrations (mg/ml) was determined. The results are shown in Figure 21. The results show that AbfC activity reached maximum at substrate concentration of 8 mg/ml WSP.
pH Activity Studies
The effect of pH on the activity of the arabinofuranosidase of the present invention was investigated using water soluble pentosan (10 mg/ml) from wheat as a substrate in 50 mM citric acid sodium phosphate buffer. The incubation time was 15 minutes. The arabinofuranosidase of the present invention was observed to have a wide pH optima range of from about 2.5 to about 7.0 (see Figure 20), more especially from about 3.3 to about 4.6, more especially about 4.
Temperature Activity Studies
The effect of temperature on the activity of the arabinofuranosidase of the present invention was investigated using water soluble pentosan (10 mg/ml) from wheat as a substrate in 50 mM sodium acetate at a pH of 5.0. The incubation time was 15 minutes. The arabinofuranosidase of die present invention was observed to have an optimal activity at a temperature of from about 40°C to about 60°C, more especially from about 45°C to about 55°C, more especially about 50°C (Figure 22). The enzyme is still active at about 10°C and showed residual activity at 70°C and 80°C.
Amino acid sequencing of the arabinofuranosidase
The enzyme was digested with endoproteinase Lys-C sequencing grade from Boehringer Mannheim using a modification of the method described by Stone & Williams 1993 (Stone, K.L. and Williams, K.R. (1993). Enzymatic digestion of Proteins and HPLC Peptide Isolation. In : Matsudaira P. (Editor). A practical Guide to Protein and Peptide Purification for Microsequencing. Second Edition. Academic Press, San Diego 1993. pp 45-73).
Freeze dried β-arabinofuranosidase (0.4 mg) was dissolved in 50 μl of 8M urea, 0.4 M NH4HCO3, pH 8.4. After overlay with N2 and addition of 5 μl of 45 Mm DTT, the protein was denatured and reduced for 15 min at 50°C under N2. After cooling to RT, 5 μl of 100 Mm iodoacetamide was added for the cysteines to be derivatised for 15 min at RT in the dark under N2. Subsequently, 90 μl of water and 5 μg of endoproteinase Lys-C in 50 μl of 50 Mm Tricine and 10 mM EDTA, pH 8.0, was added and the digestion was carried out for 24h at 37°C under N2. The resulting peptides were separated by reversed phase HPLC on a VYDAC C18 column (0.46 x 15 cm; 10 μm; The Separations Group; California) using solvent A: 0.1 % TFA in water and solvent B: 0.1 % TFA in acetonitrile. Selected peptides were rechromatographed on a Develosil C18 column (0.46 x 10 cm; 3μm) using the same solvent system prior to sequencing on an Applied Biosystems 476A sequencer using pulsed-liquid fast cycles.
The following peptide sequences were found:
SEQ I.D. No. 4 SEQ I.D. No. 5 SEQ I.D. No. 6 SEQ I.D. No. 7 SEQ I.D. No. 8
Isolation of a PCR clone of a fragment of the gene
PCR primers were synthesised using an Applied Biosystems DNA synthesiser model 392. In this regard, PCR primers were synthesized from one of the found peptide sequences, namely SEQ ID No. 5. The primers were:
One primer from EMTAQA (reversed)
SEQ ID NO. 9 GCY TGN GCN GTC ATY TC
17 mer 64 mix
One primer from MIVEAIG
SEQ ID NO. 10 ATG ATH GTN GAR GCN ATH GG
20 mer 288 mix
PCR amplification was performed with 100 pmol of each of these primers in 100 μl reactions using Amplitaq polymerase (PERKIN ELMER). The following program was:
STEP TEMP TIME
Steps 2-4 were repeated for 40 cycles. PCR reactions were performed on a PERKIN ELMER DNA Thermal Cycler.
A 100 bp amplified fragment was isolated and cloned into a pT7-Blue T-vector, according to the manufacturers instructions (Novagen).
Isolation of A. niger genomic DNA
lg. of frozen A. niger mycelium was ground in a mortar under liquid nitrogen. Follow¬ ing evaporation of the nitrogen cover, the ground mycelium was extracted with 15ml of an extraction buffer (lOOmM Tris-Hcl, pH 8.0, O.50mM EDTA, 500mM NaCl, lOmM β-mercaptoethanol) containing 1ml 20% sodium dodecyl sulphate. After incubation at 65°C for 10 min. 5ml 5M KAc. pH 5.0, was added and the mixture further incubated, after mixing, on ice for 20 mins. After extraction, the mixture was centrifuged for 20 mins. and die supernatant mixed with 0.6 vol. isopropanol to precipitate the extracted DNA. After further centrifugation for 15 mins. the DNA pellet was dissolved in 0.7 ml TE (lOmM Tris, HCI pH 8.0, ImM EDTA) and precipitated with 75 μl 3M NaAc, pH 4.8, and 500 μl isopropanol.
After centrifugation the pellet was washed with 70% ETOH and dried under vacuum. The DNA was dissolved in 200 μl TE and stored at -20°C.
Construction of a library
20 μg genomic DNA was partly digested with Tsp509I, which gives ends which are compatible with EcoRl ends. The digested DNA was separated on a 1 % agarose gel and fragments of 4-10 kb was purified. A λZAPII £ ?RI/CIAP kit from Stratagene was used for library construction according to the manufacturers instructions. 2 μl of the ligation (totally 5 μl) was packed with Gigapack Gold II packing extract from Stratagene. The library contained 650,000 independent clones. Screening of the library
2 X 50,000 pfu was plated on NZY plates and plaquelifts were done on Hybond N sheets (Amersham). Plaquelifts were done in duplicates. The sheets were hybridized with the PCR clone labelled widi 2P dCTP (Amersham) using Ready-to-go labelling kit from Pharmacia. Positive clones were reckoned only when hybridization was detected on both sheets. The gene was sequenced, and the found sequence showed that all of the peptides sequenced were coded by the found sequence.
Sequence information
SEQ. ID. No. 12 presents die promoter sequence, the enzyme coding sequence, die terminator sequence and d e signal sequence and die amino acid sequence of the enzyme of the present invention.
Arabinofuranosidase assay
Two different arabinoxylan preparations from wheat flour, Wheat Insoluble Pentosan (WIP) and Wheat soluble Pentosan (WSP), were degraded with the arabinofuranosidase enzyme of the present invention alone and in combination with an endoxylanase purified from A. niger. The assays were done on 1 % substrate in 50 Mm 50 Mm Na-acetate buffer at pH 5.0. The reactions were performed at 30 °C for 2.5 hours. The reactions were stopped by addition of 3 vol. ed anol which precipitates the high molecular weight material. The samples were centrifuged and d e supernatants were collected, dried under vacuum and resuspended in 0.5 ml distilled water. The samples were diluted 1 : 1 in water and analysed on a Chromopack Carbohydrate Pb column (300X7.8 mm, cat. 29010) using Shimadzu C-R4A Chromatopac HPLC system using a Shimadzu RI D-6A refractive index detector in accordance with the suppliers instructions.
The column was calibrated using a standard composed of 0.48 mg/ml xylotriose, 0.48 mg/ml xylobiose, 0.60 mg/ml xylose and 0.58 mg/ml L-arabinose. The peaks were identified and quantified using die software supplied with the equipment. Results - Liberated saccharides from Wheat Insoluble Pentosan
Substrate 1 % WIP in 50 Mm Na-acetate buffer pH 5.0. Values are expressed in mg/ml.
abfC denotes the enzyme according to the present invention; and xyl denotes the xylanase described before.
Results - Saccharides liberated from Wheat Soluble Pentosan
Substrate 1 % WSP in 50 Mm Na-acetate buffer pH 5.0. Values are expressed in mg/ml.
abfC denotes d e enzyme according to the present invention; and xyl denotes the xylanase described before. Figure 17 shows HP-TLC profiles of the AbfC enzyme acting synergistically with Xylanase A. In this Figure, the following abbreviations are used: water-soluble pentosan (WSP); water-insoluble pentosan (WIP); and oat xylan as substrate. The standards were: X- xylose; X2- xylobiose; X3- xylotriose; A- arabinose.
Figure 18 shows the HPLC analysis of hydrolysis products using 1 % oat spelt xylan as d e substrate. Figure 18(a) and Figure 18(b) show the products when the AbfC enzyme and the xylanase enzyme respectively were used alone. Figure 18(c) show the products when the AbfC enzyme and the xylanase enzyme when combined.
The results of these experiments provide two important findings.
First the enzyme of the present invention liberates arabinose, in particular L- arabinose, from arabinoxylan.
Second the combined actions of die enzyme according to die present invention with the endoxylanase is significantly higher than the sum of their individual action. Accordingly, the two enzymes affect each others enzymatic activities in a synergistic fashion.
Induction of the AbfC gene: Identification of inducers
The regulation of transcription of the AbfC encoding gene of Aspergillus niger was studied using a strain containing a fusion of the AbfC promoter to the j3-glucuronidase encoding gene (uid A) of E coli.
GUS producing transformants were grown on different carbon sources and assayed bodi qualitatively and quantitatively for the ability to hydrolyse p-nitrophenol glucuronide.
The results are shown below: CARBON SOURCE GUS ACTIVITY AFTER 24 HOURS INDUCTION (1 %) (units/mg)
The results show that die AbfC promoter is switched on after 24 hours when grown in die presence of xylose, xylo-oligomer 70, methyl-xylopyranoside, arabinose and arabitol. These studies also suggest that mediyl-xylopyranoside is the natural and strongest inducer of this promoter.
The AbfC promoter is strongly repressed by glucose and is dierefore under carbon catabolite repression. However, unlike all the published promoters for arabinofuranosidases, which are induced by arabinose and arabitol, the AbfC promoter of the present invention is regulated strongly by the intermediates in xylose metabolism. Accordingly, the present invention also covers an arabinofuranosidase promoter wherein the promoter is inducible by an intermediate in xylose metabolism. Effects of different promoter deletions on the regulation of the expression of the AbfC gene
To study the regulation at the molecular level, experiments were set up to detect possible upstream regulating sequences required for expression of the AbfC gene. A series of plasmids wid deletions in the 5' upstream region of the gene was constructed (see Figure 12). The E coli uid A gene was used as the reporter gene and a qualitative GUS assay was performed.
The results indicated that the truncated AbfC promoter of 590 bp contains sufficient information for the inducibility of the AbfC gene and its regulation. Deletion of 100 bps sequence from die Xma 111 to the BamHX sites of the promoter led to a reduction in activity of this promoter. Therefore, this 100 bps area is important for good levels of gene expression. Deletion of 290 bps before the ATG identified this region to be important but not sufficient to abolish the activity of this promoter. All the transformants analysed containing d is promoter construct showed very pale blue when tested (+- GUS). This region is as follows:
-170 T C A T C C A A T A T
As seen, this region contains the CCAAT element and is a putative target for a general transcriptional activator. This sequence is similar to the nuclear protein binding sites found in two starch inducible promoters: the Aspergillus niger glucoamylase gene and die Aspergillus oryzae amylase gene as well as the amdS gene of Aspergillus nidulans.
HETEROLOGOUS PROTEIN PRODUCTION USING ASPERGILLUS NIGER TRANSFORMED WITH THE AbfC PROMOTER AND THE AbfC SIGNAL SEQUENCE
Transformation of Aspergillus Niger
The protocol for transformation of A. niger was based on the teachings of Buxton,F.P. , Gwynne D.I. , Davis, R.W. 1985 (Transformation of Aspergillus niger using the argB gene oi Aspergillus nidulans. Gene 37:207-214), Daboussi,M.J. , Djeballi,A. , Gerlinger, C , Blaiseau, P.L. , Cassan, M. , Lebrun, M.H. , Parisot, D. , Brygoo,Y. 1989 (Transformation of seven species of filamentous fungi using the nitrate reductase gene of Aspergillus nidulans. Curr. Genet. 15:453-456) and Punt, P.J. , van den Hondel, C.A.M.J.J. 1992 (Transformation of filamentous fungi based on hygromycin B and Phleomycin resistance markers. Meth. Enzym. 216:447-457).
For the purification of protoplasts, spores from one PDA (Potato Dextrose Agar - from Difco Lab. Detroit) plate of fresh sporulated N400 (CBS 120.49, Centraalbureau voor Schimmelcultures, Baarn) (7 days old) are washed off in 5-10 ml water. A shake flask with 200 ml PDC (Potato Dextrose Broth, Difco 0549-17-9, Difco Lab. Detroit) is inoculated with this spore suspension and shaken (250 rpm) for 16-20 hours at 30 °C.
The mycelium is harvested using Miracloth paper and 3-4 g wet mycelium are transferred to a sterile petri dish with 10 ml STC (1.2 M sorbitol, 10 mM Tris Hcl pH 7,5, 50 Mm CaCl2) with 75 mg lysing enzymes (Sigma L-2265) and 4500 units lyticase (Sigma L- 8012).
The mycelium is incubated with the enzyme until die mycelium is degraded and die protoplasts are released. The degraded mycelium is then filtered through a sterile 60 μm mesh filter. The protoplasts are harvested by centrifugation 10 min at 2000 rpm in a swing out rotor. The supernatant is discarded and the pellet is dissolved in 8 ml 1.5 M MgSO4, and d en centrifuged at 3000 rpm for 10 min. The upper band, containing die protoplasts is transferred to another tube, using a transfer pipette and 2 ml 0.6 M KC1 is added. Carefully 5 ml 30% sucrose is added on the top and the tube is centrifuged 15 min at 3000 rpm.
The protoplasts, lying in the interface band, are transferred to a new tube and diluted with 1 vol. STC. The solution is centrifuged 10 min at 3000 rpm. The pellet is washed twice with STC, and finally solubilized in 1 ml STC. The protoplasts are counted and eventually concentrated before transformation.
For the transformation, 100 μl protoplast solution (106-107 protoplasts) are mixed with 10 μl DNA solution containing 5- 10 μg DNA and incubated 25 min at room temperature. Then 60 % PEG-4000 is carefully added in portions of 200 μl, 200 μ and 800 μl. The mixture is incubated 20 min at room temperature. 3 ml STC is added to the mixture and carefully mixed. The mixture is centrifuged 3000 rpm for 10 min.
The supernatant is removed and the protoplasts are solubilized in the remaining of the supernatant. 3-5 ml topagarose is added and the protoplasts are quickly spread on selective plates.
AbfC promoter and heterologous gene expression
The expression vector pXP-Amy (Figure 13) contains the 2.1 kb α-amylase encoding gene from Thermomyces lanuginosus cloned downstream of the AbfC promoter (2.1 kb) and upstream of the Xylanase A terminator. This vector together with the hygromycin gene as a selectable marker was used for co-transformation experiments to test the functionality of die AbfC promoter.
The best transformant was accumulated in shake flask experiments at least 1 gram per litre of α-amylase in the culture media. Starch degrading activity was then detected widiin 48 hours and a peak of enzyme activity is observed at 4 days of growth on sugar beet pulp and wheat bran (Figure 15). AbfC signal sequence functions in protein secretion
An expression construct containing the signal peptide of the AbfC gene translationally fused to die mature α-amylase from T. lanuginosus was prepared and expression of this construct in the production strains was observed. In this regard, the translational fusion construct pXPXss-Amy (Figure 14) was placed under the transcriptional control of the AbfC promoter and the xylanase A termination signal. The incorporation of an endogenous signal peptide resulted in increased detectability of co-transformants expressing both amylase and the hygromycin resistance marker. The endogenous signal peptide directed die secretion of amylase out of the cell.
Substrate Specificity of AbfC Protein
The substrate specificity of the purified AbfC was determined using arabinose containing hemicelluloses: arabinoxylans from wheat, oat and larch, branched and debranched arabinans; arabinogalactan, sugar beet pectin, and xyloglucan.
The HPLC and HP-TLC results are shown in Figure 16, in which the following abbreviations are used: WSP - water-soluble pentosan, WIP - water-insoluble pentosan, AG - arabinogalactan, deB-A - debranched arabinan. The standards used were: A- arabinose, X- xylose.
The results indicate diat arabinose is the hydrolysis product from arabinoxylans. No hydrolysis products were released from arabinogalactan, debranched arabinan or xyloglucan. Arabinose was released as a hydrolysis product from branched arabinan. AbfC is therefore a 1,2/1,2 debranching enzyme and it has no activity towards linear 1 ,5 α-linked L-arabinofuranose residues found in debranched arabinans and arabinogalactan. This enzyme also releases a product when pectin is used as the substrate. It is believed that diis product is an arabinose containing ferulic acid or an arabinobiose. Reduction of Viscosity By AbfC
The results for the substrate specificity studies also suggest that the enzyme of the present invention could be used to reduce the viscosity of feeds. In this regard, the enzyme would reduce the viscosity of branched substrates by removing the branches but not the backbone of that substrate. This is in contrast to the known viscosity modifiers which degrade the substrate backbone.
Accordingly, the present invention covers a process of reducing the viscosity of a branched substrate wherein the enzyme degrades the branches of the substrate but not the backbone of the substrate.
In particular, the present invention covers the use of the enzyme of the present invention as a viscosity modifier.
In this regard, an experiment was carried out to investigate the reduction of viscosity of the water-soluble pentosan fraction from wheat flour by arabinofuranosidase. In this experiment, 6 ml water-soluble pentosan was incubated with 100 μl of AbfC for 20 hours, 20°C at pH 5.5.
The results (see Figure 19) show that the enzyme of the present invention can be used to reduce the viscosity of pectins, especially pectins that are used in beverages - such as fruit juices.
Accordingly, d e present invention covers the use of the enzyme of the present invention to reduce the viscosity of pectin.
ANTIBODY PRODUCTION
Antibodies were raised against the enzyme of the present invention by injecting rabbits with the purified enzyme and isolating die immunoglobulins from antiserum according to procedures described according to N Harboe and A Ingild ("Immunization, Isolation of Immunoglobulins, Estimation of Antibody Titre" In A Manual of Quantitative Immunoelectrophoresis, Methods and Applications, N H Axelsen. et al (eds.), Universitetsforlaget, Oslo, 1973) and by T G Cooper ("The Tools of Biochemistry" , John Wiley & Sons, New York, 1977).
SUMMARY
Even though it is known that Aspergillus niger produces arabinofuranosidases, the present invention provides a novel and inventive arabinofuranosidase, as well as the coding sequence dierefor and the promoter for that sequence. An important advantage of the present invention is that the enzyme can be produced in high amounts.
In addition, d e promoter and die regulatory sequences (such as the signal sequence and d e terminator) can be used to express or can be used in the expression of GOIs in organisms, such as in A. niger.
The arabinofuranosidase of die present invention is different from the arabinofuranosidases previously known. In this regard, the previous described arabinofuranosidases - such as those of EP-A-0506190 - are characterised by their ability to degrade arabinan, and are assayed using p-nitrophenyl-arabinoside.
The arabinofuranosidase of the present invention does not degrade arabinan, and only a minor activity is seen on p-nitrophenyl-arabinoside.
In contrast, the arabinofuranosidase of die present invention is useful for degrading arabinoxylan. Therefore, the arabinofuranosidase of the present invention is quite different from the previous isolated arabinofuranosidases.
More in particular, the enzyme of the present invention is capable of specifically cleaving arabinose from the xylose backbone of arabinoxylan. The enzyme of the present invention is useful as it can improve processes for preparing foodstuffs and feeds as well as die foodstuffs and feeds themselves. For example, the enzyme of the present invention may be added to animal feeds which are rich in arabinoxylans. When added to feeds (including silage) for monogastic animals (e.g. poultry or swine) which contain cereals such as barley, wheat, maize, rye or oats or cereal by-products such as wheat bran or maize bran, the enzyme significantly improves the break-down of plant cell walls which leads to better utilization of the plant nutrients by the animal. As a consequence, growth rate and/or feed conversion are improved. Moreover, arabinoxylan-degrading enzymes may be used to reduce the viscosity of feeds containing arabinans. The arabinoxylan-degrading enzyme may be added beforehand to the feed or silage if pre-soaking or wet diets are preferred.
Of particular benefit is the use of the enzyme according to the present invention in combination with a xylanase, especially an endoxylanase.
A possible further application for the enzyme according to d e present invention is in the pulp and paper industry. The application of xylanases is often reported to be beneficial in the removal of lignins and terpenoids from the cellulose and hemicellulose residues of a hemicellulose backbone, an essential step in the processing of wood, wood pulp or wood derivative product for the production of paper. The addition of arabinoxylan- degrading enzymes, produced according to the present invention, to the xylanase treatment step should assist in die degradation of an arabinan-containing hemicellulose backbone and thus facilitate an improved, more efficient removal of both lignins and terpenoids. The application of arabinoxylan-degrading enzymes should be particularly advantageous in die processing of soft woods in which the hemicellulose backbone contains glucuronic acid.
The enzyme according to d e present invention is also useful as it acts in a synergistic manner with endoxylanase (see results presented above).
Od er modifications of die present invention will be apparent to those skilled in the art without departing from the scope of the invention. SEQUENCE LISTINGS
SEQ ID NO: 1 ENZYME SEQUENCE
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 296 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(n ) MOLECULE TYPE: protein
(xi). SEQUENCE DESCRIPTION: SEQ ID NO: 1:
Lys Cys Ser Leu Pro Ser
1 5
Ser Tyr Ser Trp Ser Ser Thr Asp Ala Leu Ala Thr Pro Lys Ser Gly
10 15 20
Trp Thr Ala Leu Lys Asp Phe Thr Asp Val Val Ser Asp Gly Lys His
25 30 35
He Val Tyr Ala Ser Thr Thr Asp Glu Ala Gly Asn Tyr Gly Ser Met
40 45 50
Thr Phe Gly Ala Phe Ser Glu Trp Ser Asn Met Ala Ser Ala Ser Lys 55 60 65 70
Thr Ala Thr Pro Tyr Asn Ala Val Ala Pro Thr Leu Phe Tyr Phe Lys
75 80 85
Pro Lys Ser Ile Trp Val Leu Ala Tyr Gin Trp Gly Ser Ser Thr Phe
90 95 100
Thr Tyr Arg Thr Ser Gin Asp Pro Thr Asn Val Asn Gly Trp Ser Ser
105 110 115
Glu Lys Ala Leu Phe Thr Gly Lys Leu Ser Asp Ser Ser Thr Gly Ala
120 125 130
Ile Asp Gin Thr Val Ile Gly Asp Asp Thr Asn Met Tyr Leu Phe Phe 135 140 145 150
Ala Gly Asp Asn Gly Lys He Tyr Arg Ser Ser Met Ser Ile Asp Glu 155 160 165 Phe Pro Gly Ser Phe Gly Ser Gin Tyr Glu Glu Ile Leu Ser Gly Ala
170 175 180
Thr Asn Asp Leu Phe Glu Ala Val Gin Val Tyr Thr Val Asp Gly Gly
185 190 195
Glu Gly Asn Ser Lys Tyr Leu Met Ile Val Glu Ala Ile Gly Ser Thr
200 205 210
Gly His Arg Tyr Phe Arg Ser Phe Thr Ala Ser Ser Leu Gly Gly Glu 215 220 225 230
Trp Thr Ala Gin Ala Ala Ser Glu Asp Lys Pro Phe Ala Ala Lys Pro
235 240 245
Thr Val Ala Pro Pro Gly Pro Lys Thr Leu Ala Met Val Thr Trp Phe
250 255 260
Ala Thr Thr Leu Ile Lys Pro * 265 270
SEQ ID NO : 2
NUCLEOTIDE CODING SEQUENCE
AAA TGC TCT Cπ CCA TCG TCC TAT AGT TGG AGT TCA ACC GAT GCT CTC
GCA ACT CCT AAG TCA GGA TGG ACC GCA CTG AAG GAC Tπ ACT GAT Gπ
GTC TCT GAC GGC AAA CAT ATC GTC TAT GCG TCC ACT ACT GAT GAA GCG
GGA AAC TAT GGC TCG ATG ACC Tπ GGC GCT πC TCA GAG TGG TCG AAC
ATG GCA TCT GCT AGC AAG ACA GCC ACC CCC TAC AAT GCC GTG GCT CCT
ACC CTG πC TAC πC AAG CCG AM AGC ATC TGG Gπ CTG GCC TAC CAA
TGG GGC TCC AGC ACA πC ACC TAC CGC ACC TCC CAA GAT CCC ACC AAT
GTC AAC GGC TGG TCG TCG GAG AAG GCG Cπ πC ACC GGA AAA CTC AGC
GAC TCA AGC ACC GGT GCC Aπ GAC CAG ACG GTG Aπ GGC GAC GAT ACG
AAT ATG TAT CTC πC πT GCT GGC GAC AAC GGC AAG ATC TAC CGA TCC
AGC ATG TCC ATC GAT GAA Tπ CCC GGA AGC πC GGC AGC CAG TAC GAG
GAA Aπ CTG AGT GGT GCC ACC AAC GAC CTA πC GAG GCG GTC CAA GTG
TAC ACG Gπ GAC GGC GGC GAG GGC AAC AGC AAG TAC CTC ATG ATC Gπ
GAG GCG ATC GGG TCC ACT GGA CAT CGT TAT πC CGC TCC πC ACG GCC
AGC AGT CTC GGT GGA GAG TGG ACA GCC CAG GCG GCA AGT GAG GAT AAA
CCC πC GCA GCA AAG CCA ACA GTG GCG CCA CCT GGA CCG AAG ACA πA
GCC ATG GTG ACT TGG πC GCA ACA ACC CTG ATC AAA CCA TGA
DWDDVIVD IDVWIVDDD DDDDD111D1
0i78 1191111311 VDliVDDDVD lUVDDDVDD VD1DDD1D11 DD LV11DW DD111D1DD1
08Z DDlllDDlVD WDU1V1V1 VDVIDWDDI 9W1VD1D11 VIDIDIVIVD VDD1D11D11
02 L DllVDDDDlV WIVDOIVIV VDDIVDIDID DlDlllDDW VDDD1V1111 DVDDDDVDDV
099 VDDW1WVD DDVDIDVWD DDW1DU1D 11D1WDDW VD9VD11DDV DIWWDDDD
009 DIDVIWDID DDDDDWVDD DV1DDDDD11 DIVDIVDIDD IVDDVDDDVl UDVIDDDID
Ot S VIDIWIDDD 1D1UDD1VD DV99199DD1 DDDWDDDDV DVDV1DUDD DDDWDUD1
08fr DV1DD9V191 91DVDDDVU WDDDVDIDV 1DDDD1DUV DD9VDWDW DDDDIDVIDI
OZfr DVDDDDD1U VUWDDVDV DIDIDDIDDD 1VU9VD9DD DDD1VDUDD DVDVIDDDDV
098 DD1VDDVUV DDDDDVUDD U1DVDDWD VIDVWDIDI DIWDDDDDD DVDIVIDWD
00C WVD1D9W1 U1919919D IDDWDDDDV 1DWVDDDDD DDDVIDWDI DIDDWIDDD
0t?Z DV1DUD1D1 WDiVUVW DDDWDVDU VDWIDIDID DUUDV1W DVD1VDUVD
081 DUDVUUD WDDVIDVW DU1DVDDDV DD1V1V1DU D1WD1DDU VDDDVIVIDV
~ Z\ VDIDVIVDDI DDVDD1DDU DVIVWDDID IDDWDIVDI DIDDIVDVDD IDDDVDVDVD
09 DUDW1DU DIVDDIDVIV DDIVDDDDVD IVDDDDVDVD DDD19VD991 V9W9VDD1D
3DN3.103S y310W0_.d c : ON αi 03S
600I0/96da/13d 91WO/96 OM. INFORMATION FOR SEQ ID NO: 4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide
(v) FRAGMENT TYPE: N-terminal (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:
Lys Cys Ser Leu Pro Ser Ser Tyr Ser Trp Ser Ser Thr Asp Ala Leu 1 5 10 15
Ala Thr Pro Lys 20
INFORMATION FOR SEQ ID NO: 5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 41 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide
(v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:
Tyr Leu Met He Val Gl u Ala Ile Gly Ser Thr Gly Hi s Arg Tyr Phe 1 5 10 15
Arg Ser Phe Thr Al a Ser Ser Leu Gly Gly Gl u Met Thr Al a Gi n Al a
20 25 30
Al a Ser Gl u Asp Lys Pro Phe Xaa Gly 35 40 INFORMATION FOR SEQ ID NO: 6"
(l) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 amino acids
(B) TYPE- amino acid
(C) STRANDEDNESS. single
(D) TOPOLOGY linear
(n) MOLECULE TYPE peptide
(v) FRAGMENT TYPE internal
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6.
Ser Ile Trp Val Leu Ala Tyr Gin Trp Gly Ser Ser Thr Phe Thr Tyr 1 5 10 15
Arg Thr Ser Gin Asp Pro Thr Asn Val 20 25
INFORMATION FOR SEQ ID NO: 7:
(l) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY linear
(n) MOLECULE TYPE peptide
(v) FRAGMENT TYPE internal
(xi) SEQUENCE DESCRIPTION. SEQ ID NO: 7:
Asp Ile Val Tyr Ala Ser Thr Thr Asp Glu Ala Gly Asn Tyr Gly Ser 1 5 10 15
Met Thr Phe Gly Ala Phe Ser Glu Xaa Ser Asn Met Ala Ser 20 25 30
INFORMATION FOR SEQ ID NO: 8:
(l) SEQUENCE CHARACTERISTICS:
(A) LENGTH- 41 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY linear
(ii) MOLECULE TYPE peptide
(v) FRAGMENT TYPE internal
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8
Ile Tyr Arg Ser Ser Met Ser Ile Asp Glu Phe Pro Gly Ser Phe Gly 1 5 10 15
Ser Gin Tyr Glu Glu Ile Leu Ser Gly Ala Thr Asn Asp Leu Phe Glu
20 25 30
Ala Val Gin Val Tyr Thr Val Asp Gly 35 40
INFORMATION FOR SEQ ID NO: 9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(n) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION- /desc = "OLIGONUCLEOTIDE" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6: GCYTGNGCNG TCATYTC 17
INFORMATION FOR SEQ ID NO: 10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH- 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(n) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "OLIGONUCLEOTIDE" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10: ATG ATH GTN GAR GCN ATH GG 20 INFORMATION FOR SEQ ID NO 11
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH 89 base pairs
(B) TYPE nucleic acid
(C) STRANDEDNESS double
(D) TOPOLOGY linear
(n) MOLECULE TYPE other nucleic acid
(A) DESCRIPTION /desc = "PCR fragment"
(xi) SEQUENCE DESCRIPTION SEQ ID NO 11 ATGAπGTGG AGGCGATCGG GTCCACTGGA CATCGπAπ TCCGCTCCπ CACGGCCAGC 60 AGTCTCGGTG GAGAGATGAC CGCACAGGC 89
INFORMATION FOR SEQ ID NO 12
(l) SEQUENCE CHARACTERISTICS
(A) LENGTH 2555 base pairs
(B) TYPE nucleic acid
(C) STRANDEDNESS double
(D) TOPOLOGY linear
(ii) MOLECULE TYPE DNA (genomic) (vi) ORIGINAL SOURCE
(A) ORGANISM Aspergillus niger
(B) STRAIN 3M43 (lx) FEATURE
(A) NAME/KEY CDS
(B) LOCATION 870 1757 (lx) FEATURE
(A) NAME/KEY sιg_peptιde
(B) LOCATION 870 947 (lx) FEATURE
(A) NAME/KEY mat_peptιde
(B) LOCATION 948 1754
(xi) SEQUENCE DESCRIPTION SEQ ID NO 12
CTGCAGAAGA TGGCAGTCGC CACAGCCGAT CACCCGATCC ATACTGGATG πGTAACπG 60
GAGACAGCCT GCAGATGCTC TGATGAAGGT CTGCAAATAG πCCTGGACC TCGATAGTGA 120
AGTATACCGA πCGTCAATG πGTATATCC AGCCACπTG AAAGTACCAA CTπTAGπC 180
GAπGATCAG AATACTπTG GTGTGTAACA πGACAAGCC AAAπATCAA TCTCπCTAC 240 Oil SOT OOT 96 ojd dsv [9 JΘS um 6uv u i um θμd m JΘS JΘS ^L9 dji ULD JAJ_ ZZ2I DDD 1VD WD DDl DDV DDD DVI DDV DU VDV DDV DDl DDD DDl WD DVI
06 98 08
P[V nθη [pΛ di θ i JΘS s η OJ sλη θt|d λi θL) nθη JUL ojd PL 6221 DDD 91D UD DDl DIV DDV VW DDD DW DU DVI DU DID DDV 1DD 1D9
5Z 0Z 99
[BΛ PLV usv J^l OJd J l PL m s η J S eLV UΘS PLV +9W usv ΘS 1811 919 ODD 1W DVI DDD DDV DDD VDV DW DDV 1DD 131 VD9 DIV DW DDl 09 99 09 Jl ΠLD JΘS i|d eLV D 9 d -"Ml Iθμ JΘ '[$ ^1 sv LD eLV nLD CCT! DDl DVD VD1 DU 13D DDD Ul DDV DIV DDl DDD 1V13W V99 DDD WD dsv m m UΘS BLV u i L Λ ΘLI SLH s/Cη .L dsv UΘS L Λ L Λ dsv 9801 1VD 1DV 1DV DDl DDD 1V1 DID DIV 1VD VW DDD DVD 1D1 DID UD 1VD OC 92 02 91
Jill θij dsv sλη nθη PLV Jm di /"LD UΘS s η OJd JL|1 PLV nθη PLV ZεOI 1DV Ul DVD DW DID VDD DDV 991 V99 VD1 DW 1DD 1DV VDD DID 1DD
01 9 I dsv um UΘS UΘS dJi JΘS Jλj. JΘ JΘS O d naη JΘS SΛQ sλη LV USV
686 1VD 33V V311DV 99119V 1V1 DDl DDl VDD UD 1D1 DDl VW DDD DW 8- 01- 91-
L&Λ θi|d OJ JUJ. nθη PLV ^LI J-U ΘLI ^LD UΘS UΘS n9 nθη JΘS 1176 UD Ul 33333V VU V3D UV DID DVI DIV VDD VD1 VD1 DID 9U 39V 02- 92- 92-
ΛL s η PL usv 9Md θMd η .θw C68 399 VW 3391W 3U 3U 9W 91V 9W93V1V313VW1V99393333U131 0t?8 U9UU3U V9UV339V3 U1V939V33 V91D3313U 93UVU9W 33U131331 08Z 99U1991V3 W9U1V1V1 V3V13W3919W1V319U V13131V1V3 V3913U3U 02Z 9UV93331V W1V991V1V V331V319199131U93W V9331VUU 3V3339V39V 099 V33W1WV999V919VW339W13U13 U91W9DW VDDVDUDDV D1WW33DD 009 919V1W91D 33399VW999V133333U 31V31VD13D 1V39V399V1 U9V19DD1D 0179 V191W1399131U931V93V99199331393W39DDV DVDV1DUDD D93W9U31 08fr 9V1999V191913V333VU W993V313V 1939919UV 339V3W9W 933913V131 02t7 9V933331U VUW39V3V 31913319331VU9V99933391V9U333V9V13393V 09ε 331V99VUV 33939VU39 U19V33W9 V19VW319191W3993999V31V13W3 00ε WV9199W1 U1919D1DD 1DDWD933V 19VW93399333V13W319199W1993
£ζ 60010/96J.I JLOJ 91*61/96 OAV ZZI2 9V1DDVD1VD UDDVD1DW DDVD1DDVDV DDD991W9D 9V9VD1DDD1 UDUV9WD ZII2 DV1DV19D1D V1DV9UW991DV1DDV1D V1VU9V19V 33D9DVUW D9V1WDVD1 Z902 U1D1DDV1V VDDVIDDDDI DV99WDDD11VDU9VDU WDDDVDDU 1W1DV1D99 Z66I V1V3319U1 IDDVDDDIDD 1DDD919999 U9VD1DDDV UDIVDIVDI 99199W9VD 86I DVDVDWDD1 DD1DVUUD V1DWDU3113U133131 UD1DD1VDV DDUDVU1D ZZ8I IVUDDVDDV 919VDDWD1133VU331D DDDDDDDWD DlVDDDUDl DDWDVIDVD ZI8I DDD1DVDDVD WD3333VD1 VDDDDDVD1V 1D1DDUDVD D1DDWDDU DD1V9D1D1D 0Z2 892 092 992 OJ sλη 9Li nθη jι_y_ jqi PLV θiy di JUJ. L Λ 1ΘH LV nθη un
Z9ZI VD1 V33 VW 31V DID DDV V3V V393U 99113V 91991V 339 VU V3V sλη OJd λL OJd OJd BLV L Λ um O d sλη PLV BLV θ d OJ sλη dsv 60ZI 9W 933 V99133 V33939919 V3V V339W V39 V393U 333 VW 1V9
9C2 08 922
"L9 ΘS LV BLV UL9 BLV um dJi ΠL λL ^LD θη JΘS JΘS LV um I99I 9V919V V399399V3339 V3V 9919V9 V9919931319V 39V 33993V 022 912 012 θijd ΘS βuv θμd uλi 6JV SLH λL JMl J9S ^LD 3LI LV LD L Λ 9LI EI9I DU DDl DDD 3U 1V11DD 1VD V991DV DDl DDD DIV DDD DVD UD DIV 902 002 961
}θw nθη jλi sλη JΘS USV L9 nLD ^LD ^LD dsv L Λ um jλi L ULD 9991 DIV 3133V1 DW DDV DW DDD DVD DDD D99 DVD UD DDV DVI DID WD 061 981 081 9ZI
LB BLV ΠL 9 d nθη dsv usv um LV L9 UΘS nθη ΘLI ΠLD ΠL9 uλi ZI8I DID DDD DVD DU V1D DVD DW DDV DDD 19919V 91D UV WD DVD DVI
0ZI 991 091
ULD ΘS ^LD 9Md UΘS λL O d Θ d nLD dsv 9LI UΘS Iθ-W UΘ ^ΘS 6uv 69H DVD 39V 3993U 39V V99333 Ul W91V931V 33191V 39V 331 V93 jλi ΘLI sλη λL usv dsv λLD BLV i|d 9 d nθη jλi η.θw usv JMl dsv \ZV\ 3V131V DW DDD DW DVD 399139 Ul 3U 3131V191V 1W 93V 1V9 dsv ^L99LI L um UL9 dsv ΘLI PLV L9 um UΘS UΘS dsv UΘS nθη εZCI 3V9399 UV 91993V 9V33V9 UV 33919933V 39V V313V939V 313 921 021 911 sλη λL9 m θμd nθη BLV sλη n[9 JΘS JΘS di λL usv L? usv m
92εi VW VDD DDV 3U U3 DDD DW DVD DDl DDl DDl DDD DW DID 1W 33V
6001 OI96άJJIDd 91 *6Z/96 O
8Z DDD DW UD Ul DDD DDV VU VDD UV DID
817 DVI 31V VDD VD1 V31 DID DU DDV DDD VW DDD IW DU DU DW 91V
3DN3nD3S LBuδLS π : ON αi 03S aod NOuvwaodNi (2)
86 Z DD1VDD1D 1DVDVD1WD
08Z UD13D9D99 VDWD1DWV DDDUDDUD 19VDW1VDD D1WDUVD1 1VD1VD1V91
02Z 19199DVDDV DDDIDIDDW IDDDDIDWD IDIWVIUV VDDDDDDVW 9V1D133DDD
099 VDD1DD9W9 U1WV1991 1DUDD1D1V 9DV9U991V 9V9DD1V1VD 9191DVDVDD
009 VDDWDDDV1 DVWDWDID D1D1D1VDV9 DVDD9DDD1D DDDDU1DDD DD1D1DVDU
0^9 VDDDUV1DD VDDDDV1WD VDDWU1V1 DUWD1DD1 D1DDDD9D1V VDUVDDDDD
0817 1VDDW9U1 DV1DDDDU1 W9919V9VD D1DDVDD1DD 1WDVDV1V3 V33UDDDD1
0217 DV1DDVD1VD UDDVD1DW DDV919DVDV D33991W99 9VDVD1DDD1 U9UV9WD
09ε DV1DV19D1D V1DVDUWD D1DV1DDV1D V1VUDV1DV DDD99VUW D9V1WDVD1
00ε U1D133V1V VDDVIDDDDI DVD9WDDD1 1VDUDVDU WDDDVDDU 1W19V1DDD
0f2 V1VDD1DU1 IDDVDDDIDD 1D99919999 U9VD1DDDV UDIVDIVDI DD1D9W9VD
081 DVDVDWDD1 9919VUU9 V19WDUD1 1DU1DD1D1 UD1DD1VDV DDUDVU1D
021 IVUDDVDDV D1DVDDWD1 133VU331D DDDDDDDWD DlVDDDUDl DDWDVIDVD
09 3DD1DVDDVD WDDDDDV91 VDDDD9V31V 13139UDVD DIDDWDDU 331VDD1D1D
3DN3H03S -d01VNIWy31
: ει : ON αi 03S yod NOUVWHOJNI (2)
9992 DD1VDD13 13V3VD1WD
Z882 UD1D99399 V3W913WV 993U99U3 19V3W1V99 31W9UV31 1V31V31V91
LL Z 191993V33V 93319193W 1333919W3 131WVU1V V999399VW 9V13133999 V331339W9 U1WV1991 13U39191V 93V9U991V 9V9991V1V9 91913V9V39
Z882 V93W3DDV1 DVWDWDID 3131D1VDVD DV3DDDDD1D DDDD1UDDD DD1D1DVDU
Z622 VD99UV199 VDDDDV1WD VDDWU1V1 DUWD1DD1 D1DD9D9D1V VDUVDDDDD
ZC22 1VDDWDU1 DV1DDDD1U W9919V9VD D1DDVDD1DD 1WDV9V1V3 V33U93931 ςς
600I0/96da/X3d 9I*6Σ/96 OM SEQ ID NO: 15
SIGNAL SEQUENCE
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:
Met Lys Phe Phe Asn Ala Lys Gly Ser Leu 10 Leu Ser Ser Gly Ile Tyr Leu Ile Ala Leu 20 Thr Pro Phe Val Asn Ala 26
INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
(PCT Rule I3l>~-)

Claims

1. An enzyme that is obtainable from Aspergillus, wherein the enzyme has the following characteristics: a. a MW of 33,270 D ± 50 D
b. a pI value of about 3.7
c. arabinoxylan degrading activity
d. a pH optima of from about 2.5 to about 7.0 (more especially from about 3.3 to about 4.6, more especially about 4)
e. a temperature optima of from about 40°C to about 60°C (more especially from about 45°C to about 55°C, more especially about 50°C); wherein the enzyme is capable of cleaving arabinose from the xylose backbone of an arabinoxylan.
2. An enzyme having the sequence shown as SEQ. I.D. No. 1 or a variant, homologue or fragment thereof.
3. An enzyme coded by the nucleotide sequence shown as SEQ. I.D. No. 2 or a variant, homologue or fragment thereof or a sequence complementary thereto.
4. A nucleotide sequence coding for the enzyme according to claim 1.
5. A nucleotide sequence coding for the enzyme according to claim 2.
6. A nucleotide sequence having the sequence shown as SEQ. I.D. No. 2 or a variant, homologue or fragment thereof or a sequence complementary thereto.
7. A nucleotide sequence according to any one of claims 4 to 6 operatively linked to a promoter.
8. A nucleotide sequence according to claim 7 wherein the promoter is the promoter having the sequence shown as SEQ. I.D. No. 3 or a variant, homologue or fragment thereof or a sequence complementary thereto.
9. A promoter having the sequence shown as SEQ. I.D. No. 3 or a variant, homologue or fragment thereof or a sequence complementary thereto.
10. A promoter according to claim 9 operatively linked to a GOI.
11. A promoter according to claim 10 wherein the promoter is operatively linked to a GOI, wherein the GOI comprises a nucleotide sequence according to any one of claims 4-6.
12. A terminator having the nucleotide sequence shown as SEQ. I.D. No. 13 or a variant, homologue or fragment thereof or a sequence complementary thereto.
13. A signal sequence having the nucleotide sequence shown as SEQ. I.D. No. 14 or a variant, homologue or fragment thereof or a sequence complementary thereto.
14. A construct comprising or expressing the invention according to any one of claims 1 to 13.
15. A vector comprising or expressing the invention of any one of claims 1 to 14.
16. A plasmid comprising or expressing the invention of any one of claims 1 to 15.
17. A transgenic organism comprising or expressing the invention according to any one of claims 1 to 16.
18. A transgenic organism according to claim 17 wherein the organism is a fungus.
19. A transgenic organism according to claim 18 wherein the organism is a filamentous fungus, preferably of the genus Aspergillus.
20. A transgenic organism according to claim 17 wherein the organism is a plant.
21. A process of preparing an enzyme according to any one of claims 1 to 3 comprising expressing a nucleotide sequence according to any one of claims 4-8.
22. A process according to claim 21 wherein the enzyme has the sequence shown as SEQ. I.D. No. 1 or a variant, homologue or fragment thereof, and the nucleotide sequence has the sequence shown as SEQ. I.D. No. 2 or a variant, homologue or fragment thereof or a sequence complementary thereto.
23. A process according to claim 21 or claim 22 wherein the expression is controlled (partially or completely) by use of a promoter according to claim 9.
24. A process for expressing a GOI by use of a promoter, wherein the promoter is the promoter according to claim 9.
25. Use of an enzyme according to any one of claims 1 to 3 or prepared by a process according to any one of claims 21 to 24 to degrade an arabinoxylan.
26. Use according to claim 24 wherein the enzyme is used in combination with a xylanase, preferably an endoxylanase.
27. A combination of enzymes to degrade an arabinoxylan, the combination comprising an enzyme according to any one of claims 1 to 3 or prepared by a process according to any one of claims 21 to 24 claims; and a xylanase.
28. Plasmid NCIMB 40703, or a nucleotide sequence obtainable therefrom for expressing an enzyme capable of degrading arabinoxylan or for controlling the expression thereof or for controlling the expression of another GOI.
29. A signal sequence having the sequence shown as SEQ. I.D. No. 15 or a variant, homologue or fragment thereof.
30. The use of the enzyme according to any one of claims 1 to 3 or prepared by a process according to any one of claims 21 to 24 claims, in the manufacture of a medicament or foodstuff to reduce or prevent indigestion and/or increase nutrient absorption.
31. An arabinofuranosidase enzyme having arabinoxylan degrading activity, which is immunologicaily reactive with an antibody raised against a purified arabinofuranosidase enzyme having the sequence shown as SEQ. I.D. No. 1.
EP96907403A 1995-03-17 1996-03-11 Aspergillus arabinofuranosidase Withdrawn EP0871745A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9505479 1995-03-17
GBGB9505479.7A GB9505479D0 (en) 1995-03-17 1995-03-17 Enzyme
PCT/EP1996/001009 WO1996029416A1 (en) 1995-03-17 1996-03-11 Aspergillus arabinofuranosidase

Publications (1)

Publication Number Publication Date
EP0871745A1 true EP0871745A1 (en) 1998-10-21

Family

ID=10771414

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96907403A Withdrawn EP0871745A1 (en) 1995-03-17 1996-03-11 Aspergillus arabinofuranosidase

Country Status (10)

Country Link
EP (1) EP0871745A1 (en)
JP (1) JPH11502113A (en)
CN (1) CN1198778A (en)
AU (1) AU5104396A (en)
BR (1) BR9607535A (en)
CA (1) CA2214591A1 (en)
GB (1) GB9505479D0 (en)
MX (1) MX9707072A (en)
NZ (1) NZ303970A (en)
WO (1) WO1996029416A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA99001239A (en) 1996-08-05 2003-09-12 Syngenta Mogen Bv Improved process for the production of alcoholic beverages using maltseed.
GB9704157D0 (en) 1997-02-28 1997-04-16 Danisco Expression element
PT996709E (en) 1997-04-30 2005-03-31 Leuven K U Res & Dev CELLULITIS, XYLANOLITIC AND BETAGLUCANOLYTIC ENZYMES INHIBITORS
EP0979830A1 (en) * 1998-08-12 2000-02-16 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno A novel class of xylanase inhibitors
GB9821198D0 (en) 1998-09-30 1998-11-25 Danisco Enzyme
GB9914210D0 (en) 1999-06-17 1999-08-18 Danisco Promoter
AR053066A1 (en) * 2005-04-26 2007-04-18 Novozymes As ARABINOFURANOSIDASAS
CN110423701B (en) * 2019-06-14 2022-10-28 青岛蔚蓝生物集团有限公司 Aspergillus niger strain for high yield of arabinofuranosidase

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954447A (en) * 1988-07-22 1990-09-04 The Regents Of The University Of California Feraxanase, a highly specific enzyme for hydrolysis of complex polysaccharides
PT98419B (en) * 1990-07-24 1999-01-29 Gist Brocades Nv PROCESS FOR THE PREPARATION OF DNA SEQUENCES WHICH CODE FOR XYLANESES, OF DNA CONTAINS CONTAINING THESE SEQUENCES, FOR THE TRANSFORMATION OF MICROBIAL HOSTS WITH THESE CONSTRUCTIONS, FOR THE PREPARATION OF XYLANESES BY EXPRESSION IN THESE HOSTESSES AND FOR THE DEGRADATION OF XYLANES BY ACTION OF THESE XYLANESES
IE913215A1 (en) * 1990-09-13 1992-02-25 Gist Brocades Nv Transgenic plants having a modified carbohydrate content
GB9027303D0 (en) * 1990-12-17 1991-02-06 Enzymatix Ltd Enzyme formulation
ES2120428T3 (en) * 1991-03-18 1998-11-01 Gist Brocades Nv CLONING AND EXPRESSION OF ACETYL-XYLAN ESTERASAS OF FUNGAL ORIGIN.
US5863783A (en) * 1991-03-27 1999-01-26 Gist-Brocades, N.V. Cloning and expression of DNA molecules encoding arabinan-degrading enzymes of fungal origin
SK52696A3 (en) * 1994-08-26 1997-01-08 Gist Brocades Bv Arabinoxylan degrading enzymes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9629416A1 *

Also Published As

Publication number Publication date
CN1198778A (en) 1998-11-11
NZ303970A (en) 1999-09-29
CA2214591A1 (en) 1996-09-26
JPH11502113A (en) 1999-02-23
AU5104396A (en) 1996-10-08
GB9505479D0 (en) 1995-05-03
BR9607535A (en) 1998-01-06
WO1996029416A1 (en) 1996-09-26
MX9707072A (en) 1997-11-29

Similar Documents

Publication Publication Date Title
US6143543A (en) Enzyme system comprising ferulic acid esterase from Aspergillus
Wu et al. Deletion of two endo-β-1, 4-xylanase genes reveals additional isozymes secreted by the rice blast fungus
US5770413A (en) Expression of phytase in plants
AU654147B2 (en) Cloning and expression of xylanase genes from fungal origin
US5593963A (en) Expression of phytase in plants
AU718379B2 (en) Regulating metabolism by modifying the level of trehalose-6-phosphate
EP1546316B1 (en) Mutant e. coli appa phytase enzymes and natural variants thereof, nucleic acids encoding such phytase enzymes, vectors and host cells incorporating same and methods of making and using same
Berrin et al. High-level production of recombinant fungal endo-β-1, 4-xylanase in the methylotrophic yeast Pichia pastoris
WO1998050561A1 (en) Regulating metabolism by modifying the level of trehalose-6-phosphate by inhibiting endogenous trehalase levels
Malboobi et al. A phosphate-starvation inducible β-glucosidase gene (psr3. 2) isolated from Arabidopsis thaliana is a member of a distinct subfamily of the BGA family
EP0506190B1 (en) Cloning and expression of genes encoding arabinan-degrading enzymes of fungal origin
JPH05123173A (en) Cloning, expression and use of acetylxylan- esterase derived from fungus
Juge et al. Secretion, purification, and characterisation of barley α-amylase produced by heterologous gene expression in Aspergillus niger
EP0871745A1 (en) Aspergillus arabinofuranosidase
US6077702A (en) Endo β-1,4-glucanase from Aspergillus
US6103511A (en) Lichenase and coding sequences
WO1999007863A1 (en) Processes for increasing the yield in plants
EP0983368B1 (en) Cloning of udp-galactose epimerase
WO1998006858A1 (en) BETA-1,4-ENDOGLUCANASE FROM $i(ASPERGILLUS NIGER)
US20030068805A1 (en) Endo beta-1,4-glucanase from aspergillus
MXPA97007112A (en) Endo-beta-1,4-glucanase from aspergil
US20050044589A1 (en) Process for preparing an anti-oxidant in a plant by transformation with glucan lyase DNA
CA2277776A1 (en) Expression element
WO1997016981A1 (en) Stable compositions comprising transgenic plant material
MXPA97005064A (en) Stable compositions that comprise transgeni deplant material

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970917

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 970917;LT PAYMENT 970917;LV PAYMENT 970917;SI PAYMENT 970917

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20001003